{"gene":"CBLB","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1995,"finding":"Cbl-b protein was cloned and found to directly associate with SH3 domains of multiple signaling, cytoskeletal, and adaptor proteins through its proline-rich domain. It contains a C3HC4 zinc finger (RING finger) and a nuclear localization signal, indicating a role in signal transduction regulation.","method":"Molecular cloning, SH3 domain binding assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding assays with SH3 domains, single lab, protein characterization","pmids":["7784085"],"is_preprint":false},{"year":1997,"finding":"Cbl-b interacts with Vav (a GDP/GTP exchange factor for Rac-1) through the SH3-SH2-SH3 carboxy-terminal domain of Vav and proline-rich sequences in Cbl-b. Growth factor stimulation increases Vav-Cbl-b affinity and promotes trimeric complex formation with ligand-activated receptor tyrosine kinases. Overexpression of Cbl-b inhibits Vav-mediated c-Jun N-terminal kinase activation.","method":"Yeast two-hybrid, co-immunoprecipitation, overexpression in fibroblasts, JNK activation assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus functional JNK assay, single lab","pmids":["9399639"],"is_preprint":false},{"year":1998,"finding":"CBLB is tyrosine-phosphorylated following FLT3 ligand (FL) or IL-7 stimulation in pro-B cells. Phosphorylated SHC and PI3K p85 subunit associate with CBLB upon FL stimulation. CBLB constitutively binds GRB2 predominantly through its N-terminal SH3 domain, forming a complex distinct from GRB2-CBL and GRB2-SOS1 complexes.","method":"Co-immunoprecipitation, tyrosine phosphorylation assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and phosphorylation assays, single lab, multiple binding partners characterized","pmids":["9614102"],"is_preprint":false},{"year":1999,"finding":"Cbl-b is phosphorylated and recruited to the EGFR upon EGF stimulation, and both Cbl-b and c-Cbl bind GRB2. Overexpression of Cbl-b in 32D/EGFR cells markedly inhibits EGF-induced growth by promoting apoptosis, decreases amplitude and duration of AKT activation, and shortens duration of MAP kinase and JNK activation upon EGF stimulation.","method":"In vivo phosphorylation, co-immunoprecipitation, cell growth assay, signaling pathway analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus functional growth/signaling assays, single lab","pmids":["10086340"],"is_preprint":false},{"year":1999,"finding":"Cbl-b overexpression inhibits EGFR-induced apoptosis in MDA-MB-468 cells by increasing ubiquitination and degradation of the activated EGFR, shortening the duration of EGFR activation. The inhibitory effect is reversed by blocking proteasomal degradation.","method":"Overexpression, ubiquitination assay, proteasome inhibition, EGFR phosphorylation assay","journal":"Molecular cell biology research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay plus proteasome inhibitor rescue, single lab","pmids":["10542134"],"is_preprint":false},{"year":1999,"finding":"Upon TCR engagement, Cbl-b is rapidly tyrosine-phosphorylated by Syk/Zap-70 and Src (Fyn/Lck) family kinases, with Syk inducing the most prominent effect. A Tyr-316 Cbl-binding site in Syk was required for association with and maximal phosphorylation of Cbl-b. Cbl-b constitutively binds GRB2 and associates with Crk-L upon TCR stimulation, with Crk-L binding mapped to Y655DVP and Y709KIP of Cbl-b.","method":"Co-immunoprecipitation, kinase assays, mutagenesis, Jurkat T cell stimulation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assays with mutagenesis, Co-IP in primary cells, single lab with multiple orthogonal methods","pmids":["10022120"],"is_preprint":false},{"year":2000,"finding":"Loss of Cbl-b in T cells uncouples T-cell proliferation, IL-2 production, and Vav1 phosphorylation from the requirement for CD28 co-stimulation, establishing Cbl-b as a negative regulator of activation thresholds in T lymphocytes.","method":"Gene-targeted knockout mice, T cell proliferation assay, IL-2 production, phosphorylation analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple orthogonal functional readouts, replicated in parallel paper (PMID:10646609)","pmids":["10646608"],"is_preprint":false},{"year":2000,"finding":"Cbl-b-null T cells do not require CD28 engagement for IL-2 production. The Cbl-b-null mutation fully restores T-cell-dependent antibody responses in CD28-/- mice. TCR-mediated Vav activation is significantly enhanced in Cbl-b-/- T cells, while Zap-70, Lck, Ras/MAPK, PLCγ1, and Ca2+ mobilization are not affected, indicating Cbl-b selectively suppresses TCR-mediated Vav activation to control CD28 dependence.","method":"Genetic knockout, T cell stimulation, signaling pathway analysis, genetic complementation with CD28-/- mice","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis plus orthogonal signaling pathway analysis, replicated alongside PMID:10646608","pmids":["10646609"],"is_preprint":false},{"year":2000,"finding":"Cbl-b is a RING-type E3 ubiquitin ligase that targets the p85 regulatory subunit of PI3K for ubiquitin conjugation. The RING finger of Cbl-b is essential for p85 ubiquitination. A distal C-terminal proline-rich region in Cbl-b contains the primary binding sequences for the SH3 domain of p85. Deletion of either the proline-rich region of Cbl-b or the SH3 domain of p85 severely reduces ubiquitination.","method":"In vitro ubiquitination assay, co-immunoprecipitation, domain deletion mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro ubiquitination assay with mutagenesis of both RING finger and binding domains, single lab","pmids":["11087752"],"is_preprint":false},{"year":2000,"finding":"Loss of Cbl-b in T cells relieves antigen receptor-triggered receptor clustering, lipid raft aggregation, and sustained tyrosine phosphorylation from the requirement for CD28 co-stimulation. Wiscott-Aldrich Syndrome protein (WASP) was essential for deregulated proliferation and membrane receptor reorganization of cbl-b mutant T cells. Introducing cbl-b mutation into vav1-/- background relieved functional defects of vav1-/- T cells.","method":"Genetic knockout, epistasis analysis (cbl-b x vav1 double knockout, WASP-deficient crosses), imaging, T cell functional assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with multiple double-knockout crosses and functional readouts, multiple orthogonal methods","pmids":["11070165"],"is_preprint":false},{"year":2001,"finding":"Cbl-b negatively regulates PI3K p85 in a proteolysis-independent manner through its E3 ubiquitin ligase activity. Cbl-b is involved in the recruitment of p85 to CD28 and TCR zeta. The enhanced activation of Cbl-b-/- T cells was suppressed by PI3K inhibition.","method":"Ubiquitination assay, co-immunoprecipitation, PI3K inhibitor rescue, Cbl-b-/- T cells","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ubiquitination assay plus PI3K inhibitor rescue plus Co-IP, single lab, multiple orthogonal methods","pmids":["11526404"],"is_preprint":false},{"year":2001,"finding":"Cbl-b is ubiquitinated and degraded upon EGFR activation. EGF-induced Cbl-b degradation requires intact RING finger and tyrosine kinase binding domains, and requires Cbl-b binding to the activated EGFR. Degradation of both EGFR and Cbl-b is blocked by lysosomal and proteasomal inhibitors. Grb2 and Shc are also degraded in an EGF-induced Cbl-b-dependent fashion.","method":"Ubiquitination assay, domain mutagenesis, proteasomal/lysosomal inhibitors, co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ubiquitination assay with domain mutagenesis plus pharmacological inhibitor experiments, single lab, multiple orthogonal methods","pmids":["11375397"],"is_preprint":false},{"year":2002,"finding":"A nonsense mutation in Cblb was identified by positional cloning as responsible for the Iddm/kdp1 major susceptibility locus for type 1 diabetes in the KDP rat. Transgenic complementation with wildtype Cblb significantly suppressed development of the KDP phenotype, demonstrating Cblb functions as a negative regulator of autoimmunity.","method":"Positional cloning, transgenic complementation, genetic analysis","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — positional cloning plus transgenic rescue (complementation) in a disease model","pmids":["12118252"],"is_preprint":false},{"year":2002,"finding":"c-Cbl and Cbl-b double knockout (dKO) T cells became hyperresponsive but did not show enhanced major TCR signaling pathways. DKO T cells failed to down-modulate surface TCR after ligand engagement, resulting in sustained TCR signaling; however, ligand-independent TCR internalization was normal. Trafficking of internalized TCR to the lysosome compartment was reduced. Cbl family proteins negatively regulate T cell activation by promoting clearance of engaged TCR from the cell surface.","method":"Genetic double knockout, flow cytometry, surface TCR internalization assay, lysosome trafficking assay","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — double-KO genetic model with multiple functional readouts, distinct mechanistic insight on TCR trafficking","pmids":["12415267"],"is_preprint":false},{"year":2002,"finding":"CIN85 binds to the carboxyl terminus of Cbl-b, and ligand-induced phosphorylation of Cbl-b further increases this interaction and leads to rapid, sustained recruitment of CIN85 into EGF or PDGF receptor complexes. Inhibition of CIN85-Cbl-b binding impairs Cbl-b-mediated EGFR internalization while being dispensable for Cbl-b-directed polyubiquitination of EGFR, revealing a ubiquitin ligase-independent pathway for receptor internalization.","method":"Co-immunoprecipitation, domain mapping, dominant-negative mutant, internalization assay, ubiquitination assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping, dominant-negative mutants, functional internalization and ubiquitination assays, single lab with multiple orthogonal methods","pmids":["12177062"],"is_preprint":false},{"year":2002,"finding":"Cbl-b positively regulates Btk-mediated PLC-γ2 activation in B cells. Cbl-b-deficient DT40 B cells display reduced PLC-γ2 activation and Ca2+ mobilization upon BCR stimulation. Cbl-b interacts with PLC-γ2 and facilitates its association with Btk and BLNK. Both the N-terminal TKB domain and C-terminal half of Cbl-b are required for PLC-γ2 association and Ca2+ mobilization regulation.","method":"Genetic knockout (DT40), overexpression, co-immunoprecipitation, Ca2+ mobilization assay, domain mutagenesis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO plus overexpression plus Co-IP plus domain mutagenesis plus functional assay, single lab, multiple orthogonal methods","pmids":["12093870"],"is_preprint":false},{"year":2002,"finding":"CBL-B is found in a complex with mono-ubiquitinated Vav in BCR/ABL-transformed cells. CBL-B is not associated with significant PI3K activity (unlike CBL), revealing distinct signaling complex compositions for the two paralogs. BCR/ABL downregulates CBL-B protein expression and mRNA through its kinase activity.","method":"Co-immunoprecipitation, Western blot, kinase inhibitor experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying distinct complex with mono-ubiquitinated Vav, kinase dependence established, single lab","pmids":["11857085"],"is_preprint":false},{"year":2003,"finding":"Cbl-b negatively regulates BCR signaling in B cells by targeting Syk for ubiquitination. In Cbl-b-deficient B cells, BCR cross-linking causes sustained phosphorylation of Igα, Syk, and PLC-γ2, prolonged Ca2+ mobilization, and increased ERK/JNK activation. Sustained Syk phosphorylation correlated with reduced Syk ubiquitination, establishing Cbl-b's negative regulatory role through Syk ubiquitination.","method":"Cbl-b knockout mice, BCR stimulation, co-immunoprecipitation, ubiquitination assay, imaging (BCR capping), Ca2+ mobilization","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with multiple orthogonal methods including ubiquitination assay and imaging, mechanistic link established","pmids":["12771181"],"is_preprint":false},{"year":2003,"finding":"Cbl-b translocates into lipid rafts after FcεRI engagement in mast cells. Overexpression of Cbl-b in lipid rafts inhibits FcεRI-mediated degranulation and cytokine gene transcription. A RING finger point mutation (Cys373) abrogates the suppression of degranulation but not cytokine gene transcription. Cbl-b ubiquitin ligase activity specifically downregulates Gab2 protein expression and its FcεRI-mediated phosphorylation.","method":"Lipid raft fractionation, overexpression, RING finger mutagenesis, ubiquitination assay, degranulation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — RING finger mutagenesis plus functional assays plus fractionation, single lab, multiple orthogonal methods","pmids":["14604964"],"is_preprint":false},{"year":2004,"finding":"SCF stimulation induces KIT receptor binding to Cbl proteins, which act as E3 ligases to mediate ubiquitination and degradation of KIT and themselves. Tyrosine kinase binding and RING finger domains of Cbl-b are essential for Cbl-mediated KIT ubiquitination and degradation, establishing a negative feedback loop.","method":"Co-immunoprecipitation, ubiquitination assay, domain mutagenesis, degradation assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro ubiquitination assay with domain mutagenesis, Co-IP, single lab with multiple orthogonal methods","pmids":["15315962"],"is_preprint":false},{"year":2004,"finding":"The UBA domain of Cbl-b (UBAb) interacts with ubiquitinated proteins and polyubiquitin chains in vitro, with much greater affinity for polyubiquitin chains than monoubiquitin. In contrast, the UBA domain of c-Cbl does not interact with ubiquitinated proteins. Overexpression of UBAb, but not UBAc, inhibits ubiquitin-mediated processes including degradation of EGFR, Mdm-2, and Siah-1.","method":"GST pull-down, Co-IP, in vitro ubiquitin binding, functional degradation assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro binding assays plus functional degradation assays, distinguishes Cbl-b from c-Cbl, single lab with multiple orthogonal methods","pmids":["15273720"],"is_preprint":false},{"year":2004,"finding":"Cbl-b-/- CD4+CD25- effector T cells are resistant to suppression by regulatory T cells (both Cbl-b-/- and wild-type Tregs) in vitro. Cbl-b-/- T effector cells also demonstrate resistance to TGF-β-mediated inhibition, despite normal TGF-β receptor levels and normal Smad3 phosphorylation.","method":"In vitro Treg suppression assay, TGF-β inhibition assay, flow cytometry, Cbl-b-/- mice","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with functional suppression assays and signaling analysis, single lab","pmids":["15240694"],"is_preprint":false},{"year":2007,"finding":"Cbl-b ubiquitin ligase activity is required for E3 ligase-dependent negative regulation of T cells in vivo. Selective genetic inactivation of Cbl-b E3 ligase activity phenocopies total Cbl-b ablation, causing T cell hyperactivation, spontaneous autoimmunity, and impaired T cell anergy induction in vivo, and promotes spontaneous tumor rejection.","method":"Knock-in mice with E3 ligase-dead mutation, T cell activation assays, tumor rejection model, in vivo anergy induction","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in E3-dead mutation phenocopies full KO in multiple in vivo assays, directly demonstrates catalytic function requirement","pmids":["21248250"],"is_preprint":false},{"year":2007,"finding":"Cbl-b controls the association between TLR4 and the intracellular adaptor MyD88 in monocytes after LPS stimulation. Expression of wild-type Cbl-b, but not E3 ligase-inactive Cbl-b, prevents NF-κB reporter activation in LPS-challenged monocytes. Cbl-b deficiency impairs TLR4 downregulation on neutrophil surfaces.","method":"Co-immunoprecipitation, reporter gene assay with E3 mutant, flow cytometry for surface TLR4, Cbl-b-/- mice, bone marrow chimeras","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP of TLR4-MyD88 complex, E3 mutant rescue experiment, multiple cell types analyzed, single lab","pmids":["17618294"],"is_preprint":false},{"year":2007,"finding":"Cbl-b interacts with P. aeruginosa ExoT and the ExoT substrate Crk in host cells. Following injection of ExoT into host cytosol, Cbl-b mediates ExoT polyubiquitination and proteasomal degradation. Cbl-b-/- mice (but not c-Cbl-/- mice) show increased bacterial dissemination specifically mediated by ExoT, establishing Cbl-b as essential for limiting ExoT-producing P. aeruginosa in vivo.","method":"Co-immunoprecipitation, in vitro and in vivo ubiquitination assay, mouse infection model, genetic KO comparison","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro plus in vivo evidence, genetic specificity (c-Cbl negative result), multiple orthogonal methods","pmids":["17235393"],"is_preprint":false},{"year":2008,"finding":"Cbl-b negatively regulates TCR-induced NF-κB activation via both PI3K/Akt-dependent and PKC-θ-dependent pathways. Cbl-b associates with PKC-θ upon TCR stimulation and regulates PKC-θ activation via Vav-1. PKC-θ then couples IKKs to the CARMA1-Bcl10-MALT1 complex. Hyperactivation of Akt in Cbl-b-/- cells may potentiate CARMA1-Bcl10-MALT1 complex formation.","method":"Co-immunoprecipitation, Cbl-b-/- T cells, NF-κB reporter assay, signaling pathway analysis, PKC-θ-/- crosses","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, genetic KO, reporter assay, single lab with multiple orthogonal approaches","pmids":["18227156"],"is_preprint":false},{"year":2008,"finding":"Cbl-b deficiency increases macrophage recruitment in peritonitis via LFA-1 activation. Cbl-b deficiency increases phosphorylation of T758 in the LFA-1 β2-chain, enhancing association of 14-3-3β protein with the β2-chain and activating LFA-1. Disruption of the 14-3-3/β2-integrin interaction abrogated the enhanced ICAM-1 adhesion of Cbl-b-/- macrophages.","method":"Bone marrow chimera, LFA-1/β2-integrin phosphorylation analysis, co-immunoprecipitation (14-3-3/β2 interaction), LFA-1-/- and Cbl-b-/-LFA-1-/- double-KO epistasis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — double-KO epistasis plus biochemical Co-IP plus functional adhesion assay, single lab with orthogonal methods","pmids":["18239087"],"is_preprint":false},{"year":2009,"finding":"PKC-θ associates with Cbl-b upon TCR stimulation and, after CD28 co-stimulation, mediates Cbl-b ubiquitination and proteasomal degradation in a PKC-θ kinase activity-dependent manner. PKC-θ-deficient T cell impaired responses are partially restored by concomitant loss of cblb, establishing a nonredundant antagonism between PKC-θ and Cbl-b.","method":"Co-immunoprecipitation, ubiquitination assay, kinase-dead mutant, PKCθ-/- x cblb-/- double-KO genetic epistasis, T cell activation assays","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus kinase-dead mutant plus genetic epistasis, single lab with multiple orthogonal methods","pmids":["19549985"],"is_preprint":false},{"year":2009,"finding":"Cbl-b binds to and promotes monoubiquitination of CARMA1. Ubiquitin conjugation to CARMA1 by Cbl-b disrupts CARMA1 complex formation with Bcl10 without affecting CARMA1 protein stability. CARMA1-/- NKT cells are defective in IFN-γ production. Cbl-b E3 ligase activity (RING finger) is critical for NKT anergy induction.","method":"Co-immunoprecipitation, ubiquitination assay, RING finger mutant analysis, CARMA1-/- NKT cells, IFN-γ assay","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ubiquitination assay with RING finger mutant plus Co-IP plus genetic KO, single lab with multiple methods","pmids":["19815501"],"is_preprint":false},{"year":2009,"finding":"Loss of Cbl-b in osteoclasts increases bone-resorbing activity, with increased RANKL-induced NF-κB, ERK, and p38 activation. Re-expression of Cbl-b in Cbl-b-/- osteoclast-like cells normalizes bone-resorbing activity; overexpression in WT cells inhibits bone resorption. Both functional TKB and RING finger domains are required for rescue.","method":"Genetic KO, osteoclast re-expression rescue, RING finger and TKB domain mutagenesis, bone resorption assay, RANKL signaling analysis","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — domain mutagenesis rescue experiment plus KO plus functional bone resorption assay, single lab, orthogonal methods","pmids":["19257814"],"is_preprint":false},{"year":2010,"finding":"Cbl-b is a positive modulator of GPVI-dependent platelet signaling. Cbl-b constitutively associates with PLC-γ2 and BTK in platelets. Cbl-b-/- platelets display inhibited GPVI agonist-induced aggregation, secretion, Ca2+ mobilization, and reduced PLC-γ2 and BTK activation, while Syk activation is unaffected. Cbl-b thus acts downstream of Syk but upstream of BTK and PLC-γ2.","method":"Co-immunoprecipitation, Cbl-b-/- platelets, platelet aggregation assay, Ca2+ mobilization, in vivo thrombosis model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with multiple functional platelet assays plus Co-IP, in vivo thrombosis model, single lab","pmids":["20400514"],"is_preprint":false},{"year":2011,"finding":"Autoinhibition of Cbl-b E3 activity is achieved through intramolecular interaction whereby the unphosphorylated N-terminal region masks the RING domain interaction surface with E2 ubiquitin-conjugating enzyme. Phosphorylation of Y363 (in the helix-linker region between TKB and RING domains) disrupts this interdomain interaction to expose the E2 binding surface and also enhances binding to E2 (UbcH5B) by reducing electrostatic repulsion through proximity of the phosphate group to the interaction surface.","method":"NMR, small-angle X-ray scattering (SAXS), phosphorylation-mimicking mutants, E2 binding assay","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure plus SAXS plus E2 binding assay with phosphomimetic mutants, single lab with multiple orthogonal structural and biochemical methods","pmids":["22158902"],"is_preprint":false},{"year":2013,"finding":"Cbl-b directly interacts with and ubiquitinates SMAD7, a negative regulator of TGFβ receptor signaling, targeting it for degradation. SMAD7 protein levels (but not mRNA) are elevated in cblb-/- T cells. Genetic loss of SMAD7 in cblb-/- mice restores TGFβ sensitivity in T cell cytokine responses and abrogates the tumor rejection phenotype.","method":"Co-immunoprecipitation, ubiquitination assay, SMAD7 protein/mRNA analysis, double-KO genetic epistasis (cblb-/- x SMAD7-/-), tumor rejection model","journal":"Journal of molecular cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ubiquitination assay plus Co-IP plus genetic epistasis in vivo, single lab with multiple orthogonal methods","pmids":["23709694"],"is_preprint":false},{"year":2014,"finding":"Cbl-b ubiquitinates and degrades IGF-IR in gastric cancer cells, thereby inhibiting the Akt/ERK-miR-200c-ZEB2 axis and suppressing IGF-I-induced epithelial-mesenchymal transition.","method":"shRNA knockdown, ubiquitination assay, co-immunoprecipitation, signaling pathway analysis, patient tissue correlation","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay plus Co-IP plus shRNA rescue, single lab","pmids":["24885194"],"is_preprint":false},{"year":2014,"finding":"The TAM receptor tyrosine kinases Tyro3, Axl, and Mer (Mertk) are direct ubiquitylation substrates for Cbl-b in NK cells. Cbl-b mediates NK cell inhibition downstream of TAM receptors. Genetic deletion or targeted inactivation of Cbl-b E3 ligase activity licenses NK cells to reject metastatic tumors. A TAM kinase inhibitor and warfarin exert anti-metastatic activity through the Cbl-b/TAM pathway.","method":"Ubiquitination assay, knockout mice (E3 ligase-dead knock-in), NK cell functional assays, tumor metastasis models, TAM kinase inhibitor","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ubiquitination assays with TAM substrates, E3 ligase-dead knock-in, multiple in vivo tumor models, mechanistic pathway established","pmids":["24553136"],"is_preprint":false},{"year":2014,"finding":"Cbl-b associates with Stat6 upon IL-4 ligation and targets Stat6 for ubiquitination and degradation. This process is heightened in the presence of TCR/CD28 co-stimulation. K108 and K398 of Stat6 were identified as ubiquitination sites. Loss of Cbl-b facilitates Th2 and Th9 cell differentiation; Stat6 deficiency in Cblb-/- mice abrogates hyper-Th2 responses.","method":"Co-immunoprecipitation, ubiquitination assay, site mutagenesis (K108, K398), double-KO genetic epistasis (Cblb-/- x Stat6-/-), T cell differentiation assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ubiquitination assay with site mutagenesis plus Co-IP plus genetic epistasis, single lab with multiple orthogonal methods","pmids":["24508458"],"is_preprint":false},{"year":2014,"finding":"Myostatin induces Cblb expression in a Smad3-dependent manner. Elevated Cblb results in ubiquitin-proteasome-mediated degradation of IRS1, contributing to insulin resistance. Overexpression or knockdown of Cblb has major impact on IRS1 and pAkt levels in the presence or absence of insulin.","method":"Overexpression/knockdown of Cblb, IRS1 ubiquitination assay, Western blot, Smad3-dependent reporter","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay plus knockdown/overexpression plus Smad3 pathway analysis, single lab","pmids":["24451368"],"is_preprint":false},{"year":2015,"finding":"SHP-1 is recruited to Cbl-b and dephosphorylates it upon CD3 stimulation, preventing Cbl-b tyrosine phosphorylation and subsequent ubiquitination/degradation. CD28 co-stimulation abrogates SHP-1-Cbl-b interaction. T cells lacking SHP-1 display heightened tyrosine phosphorylation and ubiquitination of Cbl-b, with decreased Cbl-b protein levels.","method":"Co-immunoprecipitation, phosphorylation assay, SHP-1-/- conditional knockout T cells, overexpression rescue, in vitro Th2 differentiation, in vivo allergy model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP plus phosphorylation assay plus conditional KO plus overexpression rescue in vitro and in vivo, single lab with multiple orthogonal methods","pmids":["26416283"],"is_preprint":false},{"year":2015,"finding":"Cbl-b and c-Cbl target the osteogenic transcription factor Osterix for ubiquitin-proteasome-mediated degradation, inhibiting BMP2-induced osteoblast differentiation in mesenchymal cells.","method":"Overexpression, co-immunoprecipitation, ubiquitination assay, osteoblast differentiation assay","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay plus Co-IP plus functional differentiation assay, single lab","pmids":["25744063"],"is_preprint":false},{"year":2016,"finding":"CBLB associates with SYK and ubiquitinates SYK, dectin-1, and dectin-2 after fungal recognition in macrophages and dendritic cells, controlling proximal CLR signaling. CBLB deficiency results in increased inflammasome activation, enhanced reactive oxygen species production, and increased fungal killing. A cell-permeable CBLB inhibitory peptide protects mice from lethal C. albicans infections.","method":"Co-immunoprecipitation, ubiquitination assay, Cblb-/- mice, inflammasome/ROS assays, in vivo infection model","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — ubiquitination assay plus Co-IP plus genetic KO plus in vivo model, replicated in parallel paper (PMID:27428899)","pmids":["27428901"],"is_preprint":false},{"year":2016,"finding":"CBLB directs polyubiquitination of dectin-1 and dectin-2 and their downstream kinase SYK, inhibiting dectin-1- and dectin-2-mediated innate immune responses against Candida albicans. CBLB mediates ubiquitination of activated CLRs through association via adapter protein FcR-γ and tyrosine kinase SYK. Ubiquitinated CLRs are sorted to lysosomes for degradation by the ESCRT system.","method":"Ubiquitination assay, co-immunoprecipitation, Cblb-/- mice, dectin-1/2-/- double-KO epistasis, ESCRT subunit knockdown, in vivo infection model","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — ubiquitination assay plus Co-IP plus genetic epistasis with multiple KOs plus in vivo model, replicated in parallel paper (PMID:27428901)","pmids":["27428899"],"is_preprint":false},{"year":2016,"finding":"Cbl-b negatively regulates CLR (Dectin-2 and Dectin-3)-mediated antifungal signaling by mediating ubiquitination of these activated CLRs through association via FcR-γ and Syk. Ubiquitinated CLRs are sorted to lysosomes via the ESCRT system. Deficiency of Cbl-b or ESCRT subunits significantly decreases CLR degradation and increases proinflammatory cytokine production.","method":"Co-immunoprecipitation, ubiquitination assay, Cblb-/- mice, ESCRT knockdown, cytokine measurement, in vivo infection","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — ubiquitination assay plus Co-IP plus Cblb-/- mice plus ESCRT knockdown, multiple orthogonal methods","pmids":["27432944"],"is_preprint":false},{"year":2016,"finding":"CD5 transmembrane receptor constitutes a key scaffold for CBL- and CBLB-mediated ubiquitylation following TCR engagement. CBLB signaling complexes were characterized over 600 seconds of TCR stimulation, identifying both known and novel CBLB-interacting partners.","method":"Affinity purification coupled to quantitative mass spectrometry, mouse genetics, biochemical analysis","journal":"Molecular systems biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative AP-MS with biochemical follow-up, single lab, novel scaffold function for CD5","pmids":["27474268"],"is_preprint":false},{"year":2018,"finding":"CBLB forms a complex with CD81, CAPN5, and other proteins in human liver cells. CBLB and CAPN5 support HCV entry at a post-binding, pre-replication step. Knockout of CBLB reduced susceptibility to all tested HCV genotypes but not to vesicular stomatitis virus or human coronavirus.","method":"Quantitative proteomics (CD81 interactome), CBLB/CAPN5 knockout, HCV infection assay","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative proteomics plus genetic knockout plus functional viral entry assay, single lab","pmids":["30024968"],"is_preprint":false},{"year":2019,"finding":"TAM receptors (Tyro3, Axl, Mer) attenuate NK cell responses via E3 ubiquitin ligase Cbl-b. Specifically, Tyro3, Axl, and Mer phosphorylate Cbl-b at tyrosine residues 133 and 363 (Tyro3 shown specifically). Gas6 ligation induces degradation of LAT1 (transmembrane adaptor for NK activating receptor signaling) in WT but not Cbl-b knockout NK cells, in a TAM kinase- and Cbl-b-dependent manner.","method":"Phosphorylation assay (Tyr133, Tyr363 on Cbl-b), Cbl-b-/- NK cells, Gas6 ligation, LAT1 degradation assay, NK cell functional assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphorylation site identification plus KO cell functional assays plus LAT1 degradation, single lab","pmids":["31531847"],"is_preprint":false},{"year":2020,"finding":"Cbl-b ubiquitinates GluN2B subunits of NMDA receptors in spinal cord dorsal horn neurons through its N-terminal TKB domain. This ubiquitination decreases GluN2B-containing NMDAR-mediated synaptic transmission. Cbl-b abundance increases from P1 to P14, limiting synaptic GluN2B during development. Peripheral inflammation causes dephosphorylation of Cbl-b at Tyr363, impairing its binding to and ubiquitylation of GluN2B, enabling reappearance of GluN2B-containing NMDARs. A phosphomimetic Cbl-b mutant suppresses GluN2B-mediated synaptic currents and inflammatory pain.","method":"Co-immunoprecipitation, ubiquitination assay, synaptic fractionation, electrophysiology, in vivo knockdown, phosphomimetic mutant, inflammatory pain model","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ubiquitination assay plus electrophysiology plus phosphomimetic mutant plus in vivo knockdown, single lab with multiple orthogonal methods","pmids":["32606037"],"is_preprint":false},{"year":2022,"finding":"Cbl-b mediates K27-linked ubiquitination of lysine 164 of STAT5a in dendritic cells, targeting STAT5 for degradation to promote cell apoptosis. c-Cbl mediates K29-linked ubiquitination of lysine 696 of STAT5a and K27-linked ubiquitination of lysine 140 and 694 of STAT5b. Loss of Cbl-b and c-Cbl in DCs results in sustained STAT5 activity, reduced Bim expression, and impaired cDC1 apoptosis.","method":"Conditional double-knockout mice (DC-specific), co-immunoprecipitation, ubiquitination assay with linkage and site specificity, apoptosis assay","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay with site specificity, Co-IP, conditional KO, single lab","pmids":["35354799"],"is_preprint":false},{"year":2023,"finding":"TCR stimulation induces formation of a molecular complex between Cbl-b and STS1 (a pH-sensitive unconventional phosphatase). The interaction depends on a proline motif in Cbl-b interacting with the STS1 SH3 domain. STS1 dephosphorylates Cbl-b-interacting phosphoproteins. Deficiency of STS1 or Cbl-b diminishes T cell sensitivity to acidic environments, promotes T cell activity in vivo, and inhibits tumor growth.","method":"Co-immunoprecipitation, phosphatase assay, proline motif mutagenesis, STS1-/- and Cbl-b-/- cells, tumor model","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mutagenesis plus phosphatase assay plus genetic KO models plus in vivo tumor model, single lab with multiple orthogonal methods","pmids":["38091950"],"is_preprint":false},{"year":2023,"finding":"Co-crystal structure of Cbl-b with the small-molecule inhibitor C7683 (an analogue of clinical candidate Nx-1607) reveals that the compound interacts with both the TKBD and LHR domains of Cbl-b, but not the RING domain, locking Cbl-b in an inactive autoinhibited conformation by acting as an intramolecular glue.","method":"X-ray crystallography (co-crystal structure), biophysical binding assays, cellular activity assays","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — co-crystal structure plus biophysical validation, defines inhibitor mechanism at atomic resolution","pmids":["38104184"],"is_preprint":false},{"year":2023,"finding":"Cbl-b independently regulates EGFR through preferential direct binding to phosphorylated Y1045 of EGFR (unlike c-Cbl which relies mainly on Grb2-dependent indirect interaction). Overexpression of E3-dead Cbl-b slows EGF-induced degradation of active EGFR and diminishes EGF-guided chemotaxis, demonstrating distinct modes of EGFR regulation by Cbl and Cbl-b.","method":"Inducible expression of E3-dead mutants, EGFR binding/ubiquitination assay, endocytosis assay, cell migration assay","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — E3-dead mutant analysis plus functional EGFR binding/trafficking/migration assays, single lab","pmids":["37903221"],"is_preprint":false},{"year":2024,"finding":"CBL and CBLB ubiquitinate ICOS in CD4+ T cells, restraining BCL6 expression by promoting ICOS degradation. Loss of CBLs allows ICOS signaling to attenuate BCL6 degradation via chaperone-mediated autophagy (CMA), promoting hyper Tfh cell responses. T cell-specific CBLs-deficient mice develop hyper Tfh responses and SLE; blockade of Tfh development prevents SLE.","method":"Conditional T cell-specific double-KO mice, ubiquitination assay (ICOS), genetic epistasis (Tfh blockade), CMA analysis, BCL6 protein stability assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay plus conditional KO plus genetic epistasis plus in vivo SLE model, single lab with multiple orthogonal methods","pmids":["38761804"],"is_preprint":false}],"current_model":"CBLB encodes a RING-type E3 ubiquitin ligase that functions as a master negative regulator of immune cell activation by ubiquitinating a broad range of substrates—including PI3K p85, Vav1, Syk, CARMA1, Stat6, SMAD7, ICOS, TAM receptors (Tyro3/Axl/Mer), dectin-1/2, TLR4-MyD88 complex components, and receptor tyrosine kinases (EGFR, IGF-IR, KIT, FLT3)—to set activation thresholds in T cells, B cells, NK cells, mast cells, and innate immune cells; its E3 activity is autoinhibited by intramolecular TKBD-RING interaction and activated by Tyr363 phosphorylation (mediated by Src/Syk family kinases or TAM receptors), and is counteracted by SHP-1-mediated dephosphorylation or degraded following CD28/PKC-θ co-stimulation, thereby coupling co-stimulatory signal strength to the amplitude and duration of downstream immune responses."},"narrative":{"mechanistic_narrative":"CBLB encodes a RING-type E3 ubiquitin ligase that functions as a master negative regulator of immune cell activation, setting the threshold and duration of antigen- and cytokine-receptor signaling across T cells, B cells, NK cells, mast cells, and innate myeloid cells [PMID:10646608, PMID:21248250, PMID:24553136]. Its catalytic role is direct and central: selective genetic inactivation of CBLB E3 activity phenocopies total ablation, producing T-cell hyperactivation, spontaneous autoimmunity, impaired anergy, and spontaneous tumor rejection [PMID:21248250]. CBLB couples co-stimulatory signal strength to response amplitude through two layered controls. First, in resting T cells it restrains TCR signaling by ubiquitinating and limiting the PI3K p85 subunit—an action that is proteolysis-independent and controls p85 recruitment to CD28/TCR-zeta—and by suppressing Vav1 activation, such that its loss uncouples proliferation and IL-2 production from CD28 co-stimulation [PMID:10646609, PMID:11087752, PMID:11526404]. Second, CBLB itself is regulated by phosphorylation: autoinhibition by an intramolecular interaction masks the RING/E2 surface, and phosphorylation of Tyr363 disrupts this interaction to license E2 (UbcH5B) engagement [PMID:22158902], while SHP-1 dephosphorylates CBLB to protect it from degradation and CD28/PKC-theta co-stimulation drives its ubiquitination and proteasomal destruction [PMID:19549985, PMID:26416283]. Through its ligase activity CBLB targets a broad substrate repertoire to terminate or tune signaling: Syk and CARMA1 in lymphocyte antigen receptor pathways [PMID:12771181, PMID:19815501], Stat6 to restrain Th2/Th9 differentiation [PMID:24508458], SMAD7 to set TGF-beta sensitivity and tumor immunity [PMID:23709694], ICOS to restrain Tfh responses and prevent lupus-like autoimmunity [PMID:38761804], TAM receptors (Tyro3/Axl/Mer) and their adaptor LAT1 in NK cells [PMID:24553136, PMID:31531847], the TLR4–MyD88 complex in monocytes [PMID:17618294], and Syk/dectin-1/dectin-2 in antifungal C-type lectin receptor signaling, routing activated receptors to lysosomal degradation via the ESCRT machinery [PMID:27428901, PMID:27428899, PMID:27432944]. Beyond immunity, CBLB ubiquitinates and degrades receptor tyrosine kinases including EGFR, KIT, and IGF-IR to limit their signaling and trafficking [PMID:11375397, PMID:15315962, PMID:24885194], and a nonsense mutation in Cblb is the causative susceptibility allele for type 1 diabetes in the KDP rat, with wild-type transgene rescuing the phenotype [PMID:12118252].","teleology":[{"year":1995,"claim":"Establishing CBLB as an adaptor-type signaling regulator answered whether it physically couples to the cytoplasmic signaling apparatus, revealing a RING-finger protein with a proline-rich domain that engages SH3-containing partners.","evidence":"Molecular cloning and SH3-domain binding assays defining the proline-rich/RING-finger architecture","pmids":["7784085"],"confidence":"Medium","gaps":["No catalytic activity demonstrated","No physiological substrate identified","Functional consequence of binding unknown"]},{"year":1997,"claim":"Linking CBLB to Vav and growth-factor receptors addressed how it intersects RTK signaling, showing it forms trimeric complexes with activated receptors and dampens Vav-driven JNK activation.","evidence":"Yeast two-hybrid, Co-IP, and JNK activation assays in fibroblasts","pmids":["9399639"],"confidence":"Medium","gaps":["Mechanism of JNK inhibition unresolved","Overexpression-based, not endogenous","No ubiquitination tested"]},{"year":1999,"claim":"Identifying the TCR-proximal kinases that phosphorylate CBLB answered how antigen-receptor engagement activates it, mapping Syk/ZAP-70 and Src-family kinase inputs and Crk-L docking sites.","evidence":"Co-IP, in vitro kinase assays, and mutagenesis in Jurkat T cells","pmids":["10022120"],"confidence":"High","gaps":["Functional outcome of each phosphosite not resolved","Catalytic activity not yet demonstrated","Endogenous substrate unknown"]},{"year":2000,"claim":"Knockout mice answered the central physiological question of CBLB function, establishing it as a negative regulator that sets the CD28 co-stimulation threshold by selectively suppressing TCR-driven Vav1 activation.","evidence":"Gene-targeted Cbl-b knockout mice with proliferation, IL-2, signaling readouts, and CD28-/- genetic complementation","pmids":["10646608","10646609","11070165"],"confidence":"High","gaps":["Molecular mechanism of Vav suppression not yet defined","Whether ubiquitination is required not yet tested","Substrate at the receptor unidentified at this stage"]},{"year":2000,"claim":"Demonstrating that CBLB is a RING-type E3 ligase targeting PI3K p85 answered how it executes negative regulation biochemically, and a later study showed this control is proteolysis-independent and governs p85 recruitment to CD28/TCR.","evidence":"In vitro ubiquitination assays, domain-deletion mutagenesis, Co-IP, and PI3K-inhibitor rescue in Cbl-b-/- T cells","pmids":["11087752","11526404"],"confidence":"High","gaps":["Non-degradative mechanism of p85 regulation incompletely defined","Ubiquitin chain linkage on p85 not characterized","Relationship to Vav suppression unresolved"]},{"year":2001,"claim":"Defining CBLB-mediated EGFR ubiquitination and reciprocal self-degradation answered how it terminates RTK signaling, showing it shortens receptor activation and is itself degraded as part of a feedback loop.","evidence":"Ubiquitination assays, domain mutagenesis, and proteasomal/lysosomal inhibitor experiments in EGFR-expressing cells","pmids":["10086340","10542134","11375397"],"confidence":"High","gaps":["In-cell ubiquitin linkage types not defined","Quantitative contribution of degradative vs non-degradative routes unclear"]},{"year":2002,"claim":"Identifying a causative Cblb nonsense mutation in the KDP rat answered whether CBLB controls autoimmunity in vivo, establishing it as a genetically validated type 1 diabetes susceptibility gene through transgenic rescue.","evidence":"Positional cloning and transgenic complementation in a spontaneous diabetes rat model","pmids":["12118252"],"confidence":"High","gaps":["Cellular target population of the diabetes phenotype not pinpointed","Substrate relevant to autoimmunity not identified here"]},{"year":2002,"claim":"Extending CBLB function to B cells and TCR trafficking answered how broadly its negative regulation operates, showing roles in PLC-gamma2 signaling and Cbl-family-dependent clearance of engaged TCR from the cell surface.","evidence":"DT40 and c-Cbl/Cbl-b double-knockout systems, Co-IP, Ca2+ mobilization, and TCR internalization/lysosome trafficking assays","pmids":["12093870","12415267","12177062"],"confidence":"High","gaps":["Distinct positive vs negative roles in B cells mechanistically separate","CIN85-dependent internalization vs ubiquitination contributions context-dependent"]},{"year":2003,"claim":"Identifying Syk as a BCR-proximal ubiquitination substrate answered how CBLB terminates antigen-receptor signaling in B cells, linking sustained Syk phosphorylation to loss of Syk ubiquitination.","evidence":"Cbl-b knockout B cells, BCR stimulation, ubiquitination assays, and imaging","pmids":["12771181"],"confidence":"High","gaps":["Syk ubiquitin chain linkage and fate not fully defined","Stoichiometry of Syk regulation unclear"]},{"year":2004,"claim":"Extending CBLB to mast cell FceRI signaling, KIT degradation, and defining its polyubiquitin-binding UBA domain answered how it operates across innate effector cells and distinguished it functionally from c-Cbl.","evidence":"Lipid-raft fractionation, RING-finger mutagenesis, ubiquitination/degradation assays, and GST pull-downs comparing UBAb vs UBAc","pmids":["14604964","15315962","15273720"],"confidence":"High","gaps":["Role of UBA polyubiquitin binding in substrate selection not fully resolved","In vivo relevance of Gab2/KIT targeting incompletely defined"]},{"year":2007,"claim":"An E3-ligase-dead knock-in answered the decisive question of whether catalytic activity underlies CBLB function in vivo, showing the catalytic mutation phenocopies full ablation in autoimmunity, anergy, and tumor rejection.","evidence":"Knock-in mice carrying an E3 ligase-dead mutation with in vivo T-cell, anergy, and tumor-rejection assays","pmids":["21248250"],"confidence":"High","gaps":["Catalytically relevant in vivo substrates not enumerated here","Cell-type-specific contributions not dissected"]},{"year":2007,"claim":"Defining CBLB control of the TLR4–MyD88 complex and ExoT degradation answered how it regulates innate antibacterial responses, requiring E3 activity for NF-kB suppression and host defense in vivo.","evidence":"Co-IP, E3-mutant reporter assays, and Cbl-b-/- mouse infection models","pmids":["17618294","17235393"],"confidence":"High","gaps":["Direct ubiquitination of TLR4/MyD88 components vs complex disruption not fully separated","Tissue-specific innate contributions incompletely mapped"]},{"year":2008,"claim":"Connecting CBLB to NF-kB regulation, PKC-theta/CARMA1 signaling, and integrin (LFA-1) activation broadened the picture of how it tunes downstream activation modules in lymphocytes and myeloid cells.","evidence":"Co-IP, Cbl-b-/- T cells, NF-kB reporters, and LFA-1/14-3-3 biochemistry with double-knockout epistasis","pmids":["18227156","18239087"],"confidence":"Medium","gaps":["Whether PKC-theta/NF-kB regulation is ubiquitination-dependent not resolved here","Direct substrate in the integrin pathway not defined"]},{"year":2009,"claim":"Identifying CARMA1 as a non-degradative monoubiquitination substrate and mapping PKC-theta-driven CBLB degradation answered how co-stimulation reciprocally controls CBLB and how it disrupts signaling complexes without proteolysis.","evidence":"Ubiquitination assays with RING mutants, Co-IP, kinase-dead mutants, and PKC-theta/Cbl-b double-knockout epistasis","pmids":["19815501","19549985","19257814"],"confidence":"High","gaps":["Generality of non-degradative monoubiquitination across substrates unclear","Determinants of degradative vs non-degradative outcomes not defined"]},{"year":2010,"claim":"Demonstrating a positive role in platelet GPVI signaling answered whether CBLB is uniformly inhibitory, showing it acts as a positive modulator downstream of Syk but upstream of BTK/PLC-gamma2 in some contexts.","evidence":"Cbl-b-/- platelets, aggregation/Ca2+ assays, Co-IP, and an in vivo thrombosis model","pmids":["20400514"],"confidence":"High","gaps":["Molecular basis of the positive (vs negative) role unresolved","Whether ligase activity is required not defined"]},{"year":2012,"claim":"The structural basis of autoinhibition answered how CBLB activity is gated, showing the unphosphorylated N-terminus masks the RING–E2 surface and Tyr363 phosphorylation relieves this and enhances E2 (UbcH5B) binding.","evidence":"NMR, SAXS, phosphomimetic mutants, and E2-binding assays","pmids":["22158902"],"confidence":"High","gaps":["Dynamics of activation in the full-length receptor-bound state not resolved","Quantitative kinetics of de-autoinhibition not defined"]},{"year":2014,"claim":"Identifying SMAD7, Stat6, IGF-IR, and the TAM receptors as substrates answered how CBLB controls TGF-beta sensitivity, Th2/Th9 differentiation, RTK-driven EMT, and NK-cell anti-metastatic activity, including therapeutic targeting of the CBLB/TAM axis.","evidence":"Ubiquitination assays with site mutagenesis, Co-IP, genetic epistasis (Cblb x Smad7, Cblb x Stat6), shRNA, E3-dead knock-in NK cells, and tumor-metastasis models","pmids":["23709694","24508458","24885194","24553136"],"confidence":"High","gaps":["Hierarchy among substrates in a given cell context not defined","In vivo contribution of IGF-IR targeting limited to cancer models"]},{"year":2015,"claim":"Defining SHP-1-mediated dephosphorylation of CBLB answered how its phosphorylation-dependent activity and stability are reversed, with CD28 co-stimulation abrogating the SHP-1 interaction.","evidence":"Co-IP, phosphorylation assays, SHP-1 conditional knockout T cells, and in vitro/in vivo allergy models","pmids":["26416283"],"confidence":"High","gaps":["Direct vs indirect SHP-1 action on specific phosphosites not fully mapped","Other phosphatases not excluded"]},{"year":2016,"claim":"Establishing CBLB control of C-type lectin receptor antifungal signaling answered how it tunes innate fungal recognition, showing ubiquitination of Syk/dectin-1/dectin-2 via FcR-gamma and ESCRT-dependent lysosomal sorting, with a CBLB inhibitory peptide protecting against Candida.","evidence":"Ubiquitination assays, Co-IP, Cblb-/- mice, dectin double-knockout epistasis, ESCRT knockdown, and in vivo infection models","pmids":["27428901","27428899","27432944"],"confidence":"High","gaps":["Substrate prioritization (receptor vs Syk) not resolved","Linkage specificity of CLR ubiquitination not defined"]},{"year":2016,"claim":"Systems-level mapping of the CBLB TCR-signaling interactome answered which scaffolds assemble CBLB complexes over time, identifying CD5 as a key scaffold for Cbl/CBLB-mediated ubiquitylation.","evidence":"Affinity-purification quantitative mass spectrometry with mouse genetics over a TCR-stimulation time course","pmids":["27474268"],"confidence":"Medium","gaps":["Functional consequence of CD5 scaffolding on specific substrates not defined","Novel partners not individually validated"]},{"year":2018,"claim":"A non-ubiquitin role in viral entry answered whether CBLB has functions beyond signaling termination, showing it acts with CD81/CAPN5 to support HCV entry at a post-binding step.","evidence":"CD81 interactome proteomics, CBLB/CAPN5 knockout, and HCV infection assays across genotypes","pmids":["30024968"],"confidence":"Medium","gaps":["Whether E3 activity is required not tested","Mechanism of entry support undefined","Direct vs indirect role unresolved"]},{"year":2020,"claim":"Extending CBLB to neurons answered whether its ubiquitin activity operates outside the immune system, showing it ubiquitinates NMDAR GluN2B in spinal cord and that inflammation-driven Tyr363 dephosphorylation drives inflammatory pain.","evidence":"Ubiquitination assays, synaptic fractionation, electrophysiology, phosphomimetic mutants, and an inflammatory pain model","pmids":["32606037"],"confidence":"High","gaps":["TKB-domain-based substrate recognition mechanism for GluN2B not fully defined","Generality to other CNS receptors unknown"]},{"year":2022,"claim":"Defining linkage- and site-specific STAT5 ubiquitination answered how CBLB and c-Cbl distinctly control dendritic cell survival, with CBLB mediating K27-linked ubiquitination of STAT5a K164 to promote apoptosis.","evidence":"DC-specific conditional double-knockout mice, Co-IP, and linkage/site-specific ubiquitination and apoptosis assays","pmids":["35354799"],"confidence":"Medium","gaps":["Functional separation of CBLB vs c-Cbl STAT5 targeting in vivo not fully resolved","Linkage determinants not mechanistically explained"]},{"year":2023,"claim":"Identifying the STS1 phosphatase complex, the EGFR-Y1045 direct binding mode, and the structural basis of small-molecule inhibition answered how CBLB activity is fine-tuned, paralog-distinguished, and therapeutically lockable in an autoinhibited state.","evidence":"Co-IP with domain mutagenesis, phosphatase assays, E3-dead EGFR trafficking assays, and a co-crystal structure with an Nx-1607 analogue","pmids":["38091950","37903221","38104184"],"confidence":"High","gaps":["In vivo significance of STS1-mediated pH sensing across tissues not defined","Generality of the Y1045 binding mode to other substrates unknown"]},{"year":2024,"claim":"Identifying ICOS as a CBL/CBLB substrate answered how it restrains follicular helper T cell programs, showing ICOS ubiquitination limits BCL6 stability and prevents lupus-like autoimmunity.","evidence":"T-cell-specific conditional double-knockout mice, ICOS ubiquitination assays, BCL6 stability analysis, and an in vivo SLE model with Tfh blockade","pmids":["38761804"],"confidence":"High","gaps":["Relative CBLB vs c-Cbl contribution to ICOS targeting not separated","Connection to chaperone-mediated autophagy of BCL6 mechanistically incomplete"]},{"year":null,"claim":"How CBLB selects among its diverse substrates, chooses ubiquitin chain linkages, and switches between degradative, trafficking-directed, and complex-disrupting (non-degradative) outcomes in a cell-type- and context-specific manner remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of substrate prioritization across immune and non-immune cells","Determinants of degradative vs non-degradative ubiquitination undefined","Quantitative rules linking co-stimulation strength to substrate fate unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[8,11,19,22,34]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[8,17,28,32,35,39]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,7,10,23]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,2,5,14]},{"term_id":"GO:0031386","term_label":"protein tag activity","supporting_discovery_ids":[20]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10,24]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[18,9]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,17,23,34,39,50]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,10,25,32]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[8,11,19,32,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12,33,50]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[46]}],"complexes":[],"partners":["VAV1","SYK","PI3K P85","GRB2","EGFR","CIN85","PKC-THETA","STS1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13191","full_name":"E3 ubiquitin-protein ligase CBL-B","aliases":["Casitas B-lineage lymphoma proto-oncogene b","RING finger protein 56","RING-type E3 ubiquitin transferase CBL-B","SH3-binding protein CBL-B","Signal transduction protein CBL-B"],"length_aa":982,"mass_kda":109.5,"function":"E3 ubiquitin-protein ligase which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and transfers it to substrates, generally promoting their degradation by the proteasome (PubMed:20525694, PubMed:40101708). Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and FCER1 (high affinity immunoglobulin epsilon receptor) signal transduction pathways (PubMed:40101708). In naive T-cells, inhibits VAV1 activation upon TCR engagement and imposes a requirement for CD28 costimulation for proliferation and IL-2 production (By similarity). Also acts by promoting PIK3R1/p85 ubiquitination, which impairs its recruitment to the TCR and subsequent activation (PubMed:11087752, PubMed:11526404). In activated T-cells, inhibits PLCG1 activation and calcium mobilization upon restimulation and promotes anergy (By similarity). Involved in LAG3-mediated inhibition of TCR signaling: following ligand-binding to LAG3, catalyzes 'Lys-63'-linked ubiquitination of LAG3, unleashing the LAG3 C-terminus from the membrane, and initiating a signaling that prevents TCR activation (PubMed:39030301, PubMed:40101708). In B-cells, acts by ubiquitinating SYK and promoting its proteasomal degradation (By similarity). Slightly promotes SRC ubiquitination (PubMed:14661060). May be involved in EGFR ubiquitination and internalization (PubMed:10086340). May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBL, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (By similarity)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q13191/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CBLB","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CBLB","total_profiled":1310},"omim":[{"mim_id":"620953","title":"METHYLMALONIC ACIDURIA, cblD TYPE; MACD","url":"https://www.omim.org/entry/620953"},{"mim_id":"620430","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 3; ADMIO3","url":"https://www.omim.org/entry/620430"},{"mim_id":"615952","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 1; ADMIO1","url":"https://www.omim.org/entry/615952"},{"mim_id":"609201","title":"UBIQUITIN-ASSOCIATED AND SH3 DOMAIN-CONTAINING PROTEIN B; UBASH3B","url":"https://www.omim.org/entry/609201"},{"mim_id":"608453","title":"CAS-BR-M MURINE ECOTROPIC RETROVIRAL TRANSFORMING SEQUENCE C; CBLC","url":"https://www.omim.org/entry/608453"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CBLB"},"hgnc":{"alias_symbol":["RNF56","Cbl-b"],"prev_symbol":[]},"alphafold":{"accession":"Q13191","domains":[{"cath_id":"1.20.930.20","chopping":"36-168","consensus_level":"medium","plddt":90.7944,"start":36,"end":168},{"cath_id":"1.10.238.10","chopping":"169-257","consensus_level":"medium","plddt":94.2811,"start":169,"end":257},{"cath_id":"3.30.40.10","chopping":"352-425","consensus_level":"high","plddt":88.2638,"start":352,"end":425},{"cath_id":"1.10.8.10","chopping":"932-971","consensus_level":"high","plddt":89.7442,"start":932,"end":971}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13191","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13191-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13191-F1-predicted_aligned_error_v6.png","plddt_mean":61.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CBLB","jax_strain_url":"https://www.jax.org/strain/search?query=CBLB"},"sequence":{"accession":"Q13191","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13191.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13191/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13191"}},"corpus_meta":[{"pmid":"10646608","id":"PMC_10646608","title":"Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10646608","citation_count":546,"is_preprint":false},{"pmid":"10646609","id":"PMC_10646609","title":"Cbl-b regulates the CD28 dependence of T-cell activation.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10646609","citation_count":497,"is_preprint":false},{"pmid":"24553136","id":"PMC_24553136","title":"The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24553136","citation_count":378,"is_preprint":false},{"pmid":"12415267","id":"PMC_12415267","title":"c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation.","date":"2002","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12415267","citation_count":320,"is_preprint":false},{"pmid":"11526404","id":"PMC_11526404","title":"Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells.","date":"2001","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11526404","citation_count":236,"is_preprint":false},{"pmid":"16212556","id":"PMC_16212556","title":"c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16212556","citation_count":215,"is_preprint":false},{"pmid":"11070165","id":"PMC_11070165","title":"Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11070165","citation_count":172,"is_preprint":false},{"pmid":"7784085","id":"PMC_7784085","title":"Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7784085","citation_count":165,"is_preprint":false},{"pmid":"11087752","id":"PMC_11087752","title":"Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11087752","citation_count":160,"is_preprint":false},{"pmid":"12118252","id":"PMC_12118252","title":"Cblb is a major susceptibility gene for rat type 1 diabetes mellitus.","date":"2002","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12118252","citation_count":147,"is_preprint":false},{"pmid":"17475912","id":"PMC_17475912","title":"Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17475912","citation_count":138,"is_preprint":false},{"pmid":"12471062","id":"PMC_12471062","title":"Identification of the gene responsible for the cblB complementation group of vitamin B12-dependent methylmalonic aciduria.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12471062","citation_count":135,"is_preprint":false},{"pmid":"21346257","id":"PMC_21346257","title":"CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21346257","citation_count":128,"is_preprint":false},{"pmid":"11375397","id":"PMC_11375397","title":"Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11375397","citation_count":122,"is_preprint":false},{"pmid":"29416005","id":"PMC_29416005","title":"miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29416005","citation_count":120,"is_preprint":false},{"pmid":"17403934","id":"PMC_17403934","title":"Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.","date":"2007","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17403934","citation_count":120,"is_preprint":false},{"pmid":"12771181","id":"PMC_12771181","title":"Cbl-b negatively regulates B cell antigen receptor signaling in mature B cells through ubiquitination of the tyrosine kinase Syk.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12771181","citation_count":117,"is_preprint":false},{"pmid":"33462140","id":"PMC_33462140","title":"Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33462140","citation_count":114,"is_preprint":false},{"pmid":"10086340","id":"PMC_10086340","title":"cbl-b inhibits epidermal growth factor receptor signaling.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10086340","citation_count":104,"is_preprint":false},{"pmid":"15240694","id":"PMC_15240694","title":"Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15240694","citation_count":104,"is_preprint":false},{"pmid":"12177062","id":"PMC_12177062","title":"CIN85 participates in Cbl-b-mediated down-regulation of receptor tyrosine kinases.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12177062","citation_count":101,"is_preprint":false},{"pmid":"17493844","id":"PMC_17493844","title":"Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b.","date":"2007","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/17493844","citation_count":99,"is_preprint":false},{"pmid":"17364027","id":"PMC_17364027","title":"Ablation of Cbl-b provides protection against transplanted and spontaneous tumors.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17364027","citation_count":98,"is_preprint":false},{"pmid":"27428901","id":"PMC_27428901","title":"Inhibition of CBLB protects from lethal Candida albicans sepsis.","date":"2016","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27428901","citation_count":94,"is_preprint":false},{"pmid":"15315962","id":"PMC_15315962","title":"Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl).","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15315962","citation_count":91,"is_preprint":false},{"pmid":"17618294","id":"PMC_17618294","title":"E3 ubiquitin ligase Cblb regulates the acute inflammatory response underlying lung injury.","date":"2007","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17618294","citation_count":85,"is_preprint":false},{"pmid":"27428899","id":"PMC_27428899","title":"Targeting CBLB as a potential therapeutic approach for disseminated candidiasis.","date":"2016","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27428899","citation_count":80,"is_preprint":false},{"pmid":"18227156","id":"PMC_18227156","title":"T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18227156","citation_count":80,"is_preprint":false},{"pmid":"21248250","id":"PMC_21248250","title":"Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21248250","citation_count":80,"is_preprint":false},{"pmid":"25815272","id":"PMC_25815272","title":"Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.","date":"2015","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25815272","citation_count":79,"is_preprint":false},{"pmid":"11864842","id":"PMC_11864842","title":"Cbl and Cbl-b in T-cell regulation.","date":"2002","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11864842","citation_count":79,"is_preprint":false},{"pmid":"22158902","id":"PMC_22158902","title":"Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22158902","citation_count":78,"is_preprint":false},{"pmid":"30442330","id":"PMC_30442330","title":"Regulation of immune responses by E3 ubiquitin ligase Cbl-b.","date":"2018","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30442330","citation_count":75,"is_preprint":false},{"pmid":"9399639","id":"PMC_9399639","title":"Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-mediated c-Jun N-terminal kinase activation.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9399639","citation_count":75,"is_preprint":false},{"pmid":"24885194","id":"PMC_24885194","title":"Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24885194","citation_count":74,"is_preprint":false},{"pmid":"15273720","id":"PMC_15273720","title":"Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15273720","citation_count":73,"is_preprint":false},{"pmid":"12842890","id":"PMC_12842890","title":"The roles of Cbl-b and c-Cbl in insulin-stimulated glucose transport.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12842890","citation_count":70,"is_preprint":false},{"pmid":"19549985","id":"PMC_19549985","title":"PKC-theta modulates the strength of T cell responses by targeting Cbl-b for ubiquitination and degradation.","date":"2009","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/19549985","citation_count":65,"is_preprint":false},{"pmid":"19815501","id":"PMC_19815501","title":"Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19815501","citation_count":64,"is_preprint":false},{"pmid":"24875217","id":"PMC_24875217","title":"E3 ubiquitin ligase Cbl-b in innate and adaptive immunity.","date":"2014","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/24875217","citation_count":62,"is_preprint":false},{"pmid":"29364514","id":"PMC_29364514","title":"E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.","date":"2018","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/29364514","citation_count":62,"is_preprint":false},{"pmid":"36750253","id":"PMC_36750253","title":"Targeting Cbl-b in cancer immunotherapy.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36750253","citation_count":59,"is_preprint":false},{"pmid":"14604964","id":"PMC_14604964","title":"Negative regulation of FcepsilonRI-mediated mast cell activation by a ubiquitin-protein ligase Cbl-b.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14604964","citation_count":59,"is_preprint":false},{"pmid":"10022120","id":"PMC_10022120","title":"Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10022120","citation_count":58,"is_preprint":false},{"pmid":"24508458","id":"PMC_24508458","title":"E3 ubiquitin ligase Cbl-b suppresses proallergic T cell development and allergic airway inflammation.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24508458","citation_count":57,"is_preprint":false},{"pmid":"32199253","id":"PMC_32199253","title":"β-Elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through miR-1323/Cbl-b/EGFR pathway.","date":"2020","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32199253","citation_count":55,"is_preprint":false},{"pmid":"18239087","id":"PMC_18239087","title":"Regulation of LFA-1-dependent inflammatory cell recruitment by Cbl-b and 14-3-3 proteins.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18239087","citation_count":52,"is_preprint":false},{"pmid":"27432944","id":"PMC_27432944","title":"E3 ubiquitin ligase Cbl-b negatively regulates C-type lectin receptor-mediated antifungal innate immunity.","date":"2016","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27432944","citation_count":50,"is_preprint":false},{"pmid":"20458601","id":"PMC_20458601","title":"Cbl-b in T-cell activation.","date":"2010","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/20458601","citation_count":48,"is_preprint":false},{"pmid":"22962608","id":"PMC_22962608","title":"Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22962608","citation_count":48,"is_preprint":false},{"pmid":"10542134","id":"PMC_10542134","title":"cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and degradation of activated receptors.","date":"1999","source":"Molecular cell biology research communications : MCBRC","url":"https://pubmed.ncbi.nlm.nih.gov/10542134","citation_count":47,"is_preprint":false},{"pmid":"9614102","id":"PMC_9614102","title":"The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9614102","citation_count":46,"is_preprint":false},{"pmid":"30024968","id":"PMC_30024968","title":"Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB.","date":"2018","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/30024968","citation_count":45,"is_preprint":false},{"pmid":"17957493","id":"PMC_17957493","title":"Methylmalonic acidaemia: examination of genotype and biochemical data in 32 patients belonging to mut, cblA or cblB complementation group.","date":"2007","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/17957493","citation_count":45,"is_preprint":false},{"pmid":"12093870","id":"PMC_12093870","title":"Cbl-b positively regulates Btk-mediated activation of phospholipase C-gamma2 in B cells.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12093870","citation_count":44,"is_preprint":false},{"pmid":"27474268","id":"PMC_27474268","title":"Co-recruitment analysis of the CBL and CBLB signalosomes in primary T cells identifies CD5 as a key regulator of TCR-induced ubiquitylation.","date":"2016","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/27474268","citation_count":44,"is_preprint":false},{"pmid":"20395198","id":"PMC_20395198","title":"Cbl-b and itch: key regulators of peripheral T-cell tolerance.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20395198","citation_count":43,"is_preprint":false},{"pmid":"18025165","id":"PMC_18025165","title":"Cbl-b regulates antigen-induced TCR down-regulation and IFN-gamma production by effector CD8 T cells without affecting functional avidity.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18025165","citation_count":43,"is_preprint":false},{"pmid":"16410054","id":"PMC_16410054","title":"Mutation and biochemical analysis of patients belonging to the cblB complementation class of vitamin B12-dependent methylmalonic aciduria.","date":"2006","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16410054","citation_count":42,"is_preprint":false},{"pmid":"20668237","id":"PMC_20668237","title":"T-cell regulation by casitas B-lineage lymphoma (Cblb) is a critical failsafe against autoimmune disease due to autoimmune regulator (Aire) deficiency.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20668237","citation_count":42,"is_preprint":false},{"pmid":"19257814","id":"PMC_19257814","title":"Loss of Cbl-b increases osteoclast bone-resorbing activity and induces osteopenia.","date":"2009","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19257814","citation_count":41,"is_preprint":false},{"pmid":"15629882","id":"PMC_15629882","title":"CBLB variants in type 1 diabetes and their genetic interaction with CTLA4.","date":"2005","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15629882","citation_count":39,"is_preprint":false},{"pmid":"26416283","id":"PMC_26416283","title":"Protein Tyrosine Phosphatase SHP-1 Modulates T Cell Responses by Controlling Cbl-b Degradation.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26416283","citation_count":38,"is_preprint":false},{"pmid":"17235393","id":"PMC_17235393","title":"The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17235393","citation_count":35,"is_preprint":false},{"pmid":"25691332","id":"PMC_25691332","title":"Ionizing radiation-inducible miR-30e promotes glioma cell invasion through EGFR stabilization by directly targeting CBL-B.","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/25691332","citation_count":35,"is_preprint":false},{"pmid":"28184224","id":"PMC_28184224","title":"Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28184224","citation_count":34,"is_preprint":false},{"pmid":"24451368","id":"PMC_24451368","title":"Myostatin induces insulin resistance via Casitas B-lineage lymphoma b (Cblb)-mediated degradation of insulin receptor substrate 1 (IRS1) protein in response to high calorie diet intake.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24451368","citation_count":34,"is_preprint":false},{"pmid":"23709694","id":"PMC_23709694","title":"Cbl-b mediates TGFβ sensitivity by downregulating inhibitory SMAD7 in primary T cells.","date":"2013","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23709694","citation_count":33,"is_preprint":false},{"pmid":"17391982","id":"PMC_17391982","title":"Regulation of peripheral T cell tolerance by the E3 ubiquitin ligase Cbl-b.","date":"2007","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17391982","citation_count":32,"is_preprint":false},{"pmid":"33195489","id":"PMC_33195489","title":"Bta-miR-223 Targeting CBLB Contributes to Resistance to Staphylococcus aureus Mastitis Through the PI3K/AKT/NF-κB Pathway.","date":"2020","source":"Frontiers in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/33195489","citation_count":32,"is_preprint":false},{"pmid":"33741730","id":"PMC_33741730","title":"CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33741730","citation_count":31,"is_preprint":false},{"pmid":"31531847","id":"PMC_31531847","title":"TAM receptors attenuate murine NK-cell responses via E3 ubiquitin ligase Cbl-b.","date":"2019","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31531847","citation_count":30,"is_preprint":false},{"pmid":"25744063","id":"PMC_25744063","title":"Cbl-b and c-Cbl negatively regulate osteoblast differentiation by enhancing ubiquitination and degradation of Osterix.","date":"2015","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/25744063","citation_count":28,"is_preprint":false},{"pmid":"16608902","id":"PMC_16608902","title":"Increased TGF-beta, Cbl-b and CTLA-4 levels and immunosuppression in association with chronic immune activation.","date":"2006","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16608902","citation_count":28,"is_preprint":false},{"pmid":"28972304","id":"PMC_28972304","title":"DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells.","date":"2017","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28972304","citation_count":27,"is_preprint":false},{"pmid":"38104184","id":"PMC_38104184","title":"The co-crystal structure of Cbl-b and a small-molecule inhibitor reveals the mechanism of Cbl-b inhibition.","date":"2023","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/38104184","citation_count":26,"is_preprint":false},{"pmid":"11857085","id":"PMC_11857085","title":"Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11857085","citation_count":26,"is_preprint":false},{"pmid":"30468278","id":"PMC_30468278","title":"Bufalin induces protective autophagy by Cbl-b regulating mTOR and ERK signaling pathways in gastric cancer cells.","date":"2019","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/30468278","citation_count":26,"is_preprint":false},{"pmid":"38091950","id":"PMC_38091950","title":"TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments.","date":"2023","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/38091950","citation_count":25,"is_preprint":false},{"pmid":"22550535","id":"PMC_22550535","title":"Releasing the brake: targeting Cbl-b to enhance lymphocyte effector functions.","date":"2012","source":"Clinical & developmental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22550535","citation_count":24,"is_preprint":false},{"pmid":"20400514","id":"PMC_20400514","title":"Cbl-b is a novel physiologic regulator of glycoprotein VI-dependent platelet activation.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20400514","citation_count":24,"is_preprint":false},{"pmid":"21558139","id":"PMC_21558139","title":"Expression and function of Cbl-b in T cells from patients with systemic lupus erythematosus, and detection of the 2126 A/G Cblb gene polymorphism in the Mexican mestizo population.","date":"2011","source":"Lupus","url":"https://pubmed.ncbi.nlm.nih.gov/21558139","citation_count":24,"is_preprint":false},{"pmid":"29940895","id":"PMC_29940895","title":"MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29940895","citation_count":23,"is_preprint":false},{"pmid":"25689493","id":"PMC_25689493","title":"N-myristoylated ubiquitin ligase Cbl-b inhibitor prevents on glucocorticoid-induced atrophy in mouse skeletal muscle.","date":"2015","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/25689493","citation_count":23,"is_preprint":false},{"pmid":"20556797","id":"PMC_20556797","title":"Functional and structural analysis of five mutations identified in methylmalonic aciduria cblB type.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20556797","citation_count":23,"is_preprint":false},{"pmid":"32606037","id":"PMC_32606037","title":"Ubiquitination and functional modification of GluN2B subunit-containing NMDA receptors by Cbl-b in the spinal cord dorsal horn.","date":"2020","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/32606037","citation_count":23,"is_preprint":false},{"pmid":"37903221","id":"PMC_37903221","title":"Cbl and Cbl-b independently regulate EGFR through distinct receptor interaction modes.","date":"2023","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/37903221","citation_count":22,"is_preprint":false},{"pmid":"25261476","id":"PMC_25261476","title":"A multiple sclerosis-associated variant of CBLB links genetic risk with type I IFN function.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25261476","citation_count":22,"is_preprint":false},{"pmid":"24351824","id":"PMC_24351824","title":"Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24351824","citation_count":22,"is_preprint":false},{"pmid":"25871390","id":"PMC_25871390","title":"Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25871390","citation_count":22,"is_preprint":false},{"pmid":"21383769","id":"PMC_21383769","title":"Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.","date":"2011","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21383769","citation_count":22,"is_preprint":false},{"pmid":"28611299","id":"PMC_28611299","title":"Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28611299","citation_count":21,"is_preprint":false},{"pmid":"33974042","id":"PMC_33974042","title":"Cbl-b deficiency prevents functional but not phenotypic T cell anergy.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33974042","citation_count":19,"is_preprint":false},{"pmid":"35354799","id":"PMC_35354799","title":"Ablation of Cbl-b and c-Cbl in dendritic cells causes spontaneous liver cirrhosis via altering multiple properties of CD103+ cDC1s.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35354799","citation_count":19,"is_preprint":false},{"pmid":"28100467","id":"PMC_28100467","title":"An essential role of CBL and CBL-B ubiquitin ligases in mammary stem cell maintenance.","date":"2017","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28100467","citation_count":19,"is_preprint":false},{"pmid":"30515972","id":"PMC_30515972","title":"LncRNA DUXAP9-206 directly binds with Cbl-b to augment EGFR signaling and promotes non-small cell lung cancer progression.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30515972","citation_count":19,"is_preprint":false},{"pmid":"24614797","id":"PMC_24614797","title":"Ubiquitin ligase Cbl-b and obesity-induced insulin resistance.","date":"2014","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/24614797","citation_count":18,"is_preprint":false},{"pmid":"30082827","id":"PMC_30082827","title":"Cbl-b deficiency provides protection against UVB-induced skin damage by modulating inflammatory gene signature.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30082827","citation_count":18,"is_preprint":false},{"pmid":"26732495","id":"PMC_26732495","title":"Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer.","date":"2015","source":"Clinical lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26732495","citation_count":18,"is_preprint":false},{"pmid":"38761804","id":"PMC_38761804","title":"Deficiency of CBL and CBLB ubiquitin ligases leads to hyper T follicular helper cell responses and lupus by reducing BCL6 degradation.","date":"2024","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/38761804","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47611,"output_tokens":13378,"usd":0.171752,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":25116,"output_tokens":8066,"usd":0.163615,"stage2_stop_reason":"end_turn"},"total_usd":0.335367,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Cbl-b protein was cloned and found to directly associate with SH3 domains of multiple signaling, cytoskeletal, and adaptor proteins through its proline-rich domain. It contains a C3HC4 zinc finger (RING finger) and a nuclear localization signal, indicating a role in signal transduction regulation.\",\n      \"method\": \"Molecular cloning, SH3 domain binding assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding assays with SH3 domains, single lab, protein characterization\",\n      \"pmids\": [\"7784085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Cbl-b interacts with Vav (a GDP/GTP exchange factor for Rac-1) through the SH3-SH2-SH3 carboxy-terminal domain of Vav and proline-rich sequences in Cbl-b. Growth factor stimulation increases Vav-Cbl-b affinity and promotes trimeric complex formation with ligand-activated receptor tyrosine kinases. Overexpression of Cbl-b inhibits Vav-mediated c-Jun N-terminal kinase activation.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, overexpression in fibroblasts, JNK activation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus Co-IP plus functional JNK assay, single lab\",\n      \"pmids\": [\"9399639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CBLB is tyrosine-phosphorylated following FLT3 ligand (FL) or IL-7 stimulation in pro-B cells. Phosphorylated SHC and PI3K p85 subunit associate with CBLB upon FL stimulation. CBLB constitutively binds GRB2 predominantly through its N-terminal SH3 domain, forming a complex distinct from GRB2-CBL and GRB2-SOS1 complexes.\",\n      \"method\": \"Co-immunoprecipitation, tyrosine phosphorylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and phosphorylation assays, single lab, multiple binding partners characterized\",\n      \"pmids\": [\"9614102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Cbl-b is phosphorylated and recruited to the EGFR upon EGF stimulation, and both Cbl-b and c-Cbl bind GRB2. Overexpression of Cbl-b in 32D/EGFR cells markedly inhibits EGF-induced growth by promoting apoptosis, decreases amplitude and duration of AKT activation, and shortens duration of MAP kinase and JNK activation upon EGF stimulation.\",\n      \"method\": \"In vivo phosphorylation, co-immunoprecipitation, cell growth assay, signaling pathway analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus functional growth/signaling assays, single lab\",\n      \"pmids\": [\"10086340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Cbl-b overexpression inhibits EGFR-induced apoptosis in MDA-MB-468 cells by increasing ubiquitination and degradation of the activated EGFR, shortening the duration of EGFR activation. The inhibitory effect is reversed by blocking proteasomal degradation.\",\n      \"method\": \"Overexpression, ubiquitination assay, proteasome inhibition, EGFR phosphorylation assay\",\n      \"journal\": \"Molecular cell biology research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay plus proteasome inhibitor rescue, single lab\",\n      \"pmids\": [\"10542134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Upon TCR engagement, Cbl-b is rapidly tyrosine-phosphorylated by Syk/Zap-70 and Src (Fyn/Lck) family kinases, with Syk inducing the most prominent effect. A Tyr-316 Cbl-binding site in Syk was required for association with and maximal phosphorylation of Cbl-b. Cbl-b constitutively binds GRB2 and associates with Crk-L upon TCR stimulation, with Crk-L binding mapped to Y655DVP and Y709KIP of Cbl-b.\",\n      \"method\": \"Co-immunoprecipitation, kinase assays, mutagenesis, Jurkat T cell stimulation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assays with mutagenesis, Co-IP in primary cells, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"10022120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Loss of Cbl-b in T cells uncouples T-cell proliferation, IL-2 production, and Vav1 phosphorylation from the requirement for CD28 co-stimulation, establishing Cbl-b as a negative regulator of activation thresholds in T lymphocytes.\",\n      \"method\": \"Gene-targeted knockout mice, T cell proliferation assay, IL-2 production, phosphorylation analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple orthogonal functional readouts, replicated in parallel paper (PMID:10646609)\",\n      \"pmids\": [\"10646608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Cbl-b-null T cells do not require CD28 engagement for IL-2 production. The Cbl-b-null mutation fully restores T-cell-dependent antibody responses in CD28-/- mice. TCR-mediated Vav activation is significantly enhanced in Cbl-b-/- T cells, while Zap-70, Lck, Ras/MAPK, PLCγ1, and Ca2+ mobilization are not affected, indicating Cbl-b selectively suppresses TCR-mediated Vav activation to control CD28 dependence.\",\n      \"method\": \"Genetic knockout, T cell stimulation, signaling pathway analysis, genetic complementation with CD28-/- mice\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis plus orthogonal signaling pathway analysis, replicated alongside PMID:10646608\",\n      \"pmids\": [\"10646609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Cbl-b is a RING-type E3 ubiquitin ligase that targets the p85 regulatory subunit of PI3K for ubiquitin conjugation. The RING finger of Cbl-b is essential for p85 ubiquitination. A distal C-terminal proline-rich region in Cbl-b contains the primary binding sequences for the SH3 domain of p85. Deletion of either the proline-rich region of Cbl-b or the SH3 domain of p85 severely reduces ubiquitination.\",\n      \"method\": \"In vitro ubiquitination assay, co-immunoprecipitation, domain deletion mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro ubiquitination assay with mutagenesis of both RING finger and binding domains, single lab\",\n      \"pmids\": [\"11087752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Loss of Cbl-b in T cells relieves antigen receptor-triggered receptor clustering, lipid raft aggregation, and sustained tyrosine phosphorylation from the requirement for CD28 co-stimulation. Wiscott-Aldrich Syndrome protein (WASP) was essential for deregulated proliferation and membrane receptor reorganization of cbl-b mutant T cells. Introducing cbl-b mutation into vav1-/- background relieved functional defects of vav1-/- T cells.\",\n      \"method\": \"Genetic knockout, epistasis analysis (cbl-b x vav1 double knockout, WASP-deficient crosses), imaging, T cell functional assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with multiple double-knockout crosses and functional readouts, multiple orthogonal methods\",\n      \"pmids\": [\"11070165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Cbl-b negatively regulates PI3K p85 in a proteolysis-independent manner through its E3 ubiquitin ligase activity. Cbl-b is involved in the recruitment of p85 to CD28 and TCR zeta. The enhanced activation of Cbl-b-/- T cells was suppressed by PI3K inhibition.\",\n      \"method\": \"Ubiquitination assay, co-immunoprecipitation, PI3K inhibitor rescue, Cbl-b-/- T cells\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ubiquitination assay plus PI3K inhibitor rescue plus Co-IP, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"11526404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Cbl-b is ubiquitinated and degraded upon EGFR activation. EGF-induced Cbl-b degradation requires intact RING finger and tyrosine kinase binding domains, and requires Cbl-b binding to the activated EGFR. Degradation of both EGFR and Cbl-b is blocked by lysosomal and proteasomal inhibitors. Grb2 and Shc are also degraded in an EGF-induced Cbl-b-dependent fashion.\",\n      \"method\": \"Ubiquitination assay, domain mutagenesis, proteasomal/lysosomal inhibitors, co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ubiquitination assay with domain mutagenesis plus pharmacological inhibitor experiments, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"11375397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A nonsense mutation in Cblb was identified by positional cloning as responsible for the Iddm/kdp1 major susceptibility locus for type 1 diabetes in the KDP rat. Transgenic complementation with wildtype Cblb significantly suppressed development of the KDP phenotype, demonstrating Cblb functions as a negative regulator of autoimmunity.\",\n      \"method\": \"Positional cloning, transgenic complementation, genetic analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — positional cloning plus transgenic rescue (complementation) in a disease model\",\n      \"pmids\": [\"12118252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"c-Cbl and Cbl-b double knockout (dKO) T cells became hyperresponsive but did not show enhanced major TCR signaling pathways. DKO T cells failed to down-modulate surface TCR after ligand engagement, resulting in sustained TCR signaling; however, ligand-independent TCR internalization was normal. Trafficking of internalized TCR to the lysosome compartment was reduced. Cbl family proteins negatively regulate T cell activation by promoting clearance of engaged TCR from the cell surface.\",\n      \"method\": \"Genetic double knockout, flow cytometry, surface TCR internalization assay, lysosome trafficking assay\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double-KO genetic model with multiple functional readouts, distinct mechanistic insight on TCR trafficking\",\n      \"pmids\": [\"12415267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CIN85 binds to the carboxyl terminus of Cbl-b, and ligand-induced phosphorylation of Cbl-b further increases this interaction and leads to rapid, sustained recruitment of CIN85 into EGF or PDGF receptor complexes. Inhibition of CIN85-Cbl-b binding impairs Cbl-b-mediated EGFR internalization while being dispensable for Cbl-b-directed polyubiquitination of EGFR, revealing a ubiquitin ligase-independent pathway for receptor internalization.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, dominant-negative mutant, internalization assay, ubiquitination assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping, dominant-negative mutants, functional internalization and ubiquitination assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"12177062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cbl-b positively regulates Btk-mediated PLC-γ2 activation in B cells. Cbl-b-deficient DT40 B cells display reduced PLC-γ2 activation and Ca2+ mobilization upon BCR stimulation. Cbl-b interacts with PLC-γ2 and facilitates its association with Btk and BLNK. Both the N-terminal TKB domain and C-terminal half of Cbl-b are required for PLC-γ2 association and Ca2+ mobilization regulation.\",\n      \"method\": \"Genetic knockout (DT40), overexpression, co-immunoprecipitation, Ca2+ mobilization assay, domain mutagenesis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus overexpression plus Co-IP plus domain mutagenesis plus functional assay, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"12093870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CBL-B is found in a complex with mono-ubiquitinated Vav in BCR/ABL-transformed cells. CBL-B is not associated with significant PI3K activity (unlike CBL), revealing distinct signaling complex compositions for the two paralogs. BCR/ABL downregulates CBL-B protein expression and mRNA through its kinase activity.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, kinase inhibitor experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying distinct complex with mono-ubiquitinated Vav, kinase dependence established, single lab\",\n      \"pmids\": [\"11857085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Cbl-b negatively regulates BCR signaling in B cells by targeting Syk for ubiquitination. In Cbl-b-deficient B cells, BCR cross-linking causes sustained phosphorylation of Igα, Syk, and PLC-γ2, prolonged Ca2+ mobilization, and increased ERK/JNK activation. Sustained Syk phosphorylation correlated with reduced Syk ubiquitination, establishing Cbl-b's negative regulatory role through Syk ubiquitination.\",\n      \"method\": \"Cbl-b knockout mice, BCR stimulation, co-immunoprecipitation, ubiquitination assay, imaging (BCR capping), Ca2+ mobilization\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with multiple orthogonal methods including ubiquitination assay and imaging, mechanistic link established\",\n      \"pmids\": [\"12771181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Cbl-b translocates into lipid rafts after FcεRI engagement in mast cells. Overexpression of Cbl-b in lipid rafts inhibits FcεRI-mediated degranulation and cytokine gene transcription. A RING finger point mutation (Cys373) abrogates the suppression of degranulation but not cytokine gene transcription. Cbl-b ubiquitin ligase activity specifically downregulates Gab2 protein expression and its FcεRI-mediated phosphorylation.\",\n      \"method\": \"Lipid raft fractionation, overexpression, RING finger mutagenesis, ubiquitination assay, degranulation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RING finger mutagenesis plus functional assays plus fractionation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"14604964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SCF stimulation induces KIT receptor binding to Cbl proteins, which act as E3 ligases to mediate ubiquitination and degradation of KIT and themselves. Tyrosine kinase binding and RING finger domains of Cbl-b are essential for Cbl-mediated KIT ubiquitination and degradation, establishing a negative feedback loop.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, domain mutagenesis, degradation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro ubiquitination assay with domain mutagenesis, Co-IP, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15315962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The UBA domain of Cbl-b (UBAb) interacts with ubiquitinated proteins and polyubiquitin chains in vitro, with much greater affinity for polyubiquitin chains than monoubiquitin. In contrast, the UBA domain of c-Cbl does not interact with ubiquitinated proteins. Overexpression of UBAb, but not UBAc, inhibits ubiquitin-mediated processes including degradation of EGFR, Mdm-2, and Siah-1.\",\n      \"method\": \"GST pull-down, Co-IP, in vitro ubiquitin binding, functional degradation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding assays plus functional degradation assays, distinguishes Cbl-b from c-Cbl, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15273720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Cbl-b-/- CD4+CD25- effector T cells are resistant to suppression by regulatory T cells (both Cbl-b-/- and wild-type Tregs) in vitro. Cbl-b-/- T effector cells also demonstrate resistance to TGF-β-mediated inhibition, despite normal TGF-β receptor levels and normal Smad3 phosphorylation.\",\n      \"method\": \"In vitro Treg suppression assay, TGF-β inhibition assay, flow cytometry, Cbl-b-/- mice\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with functional suppression assays and signaling analysis, single lab\",\n      \"pmids\": [\"15240694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Cbl-b ubiquitin ligase activity is required for E3 ligase-dependent negative regulation of T cells in vivo. Selective genetic inactivation of Cbl-b E3 ligase activity phenocopies total Cbl-b ablation, causing T cell hyperactivation, spontaneous autoimmunity, and impaired T cell anergy induction in vivo, and promotes spontaneous tumor rejection.\",\n      \"method\": \"Knock-in mice with E3 ligase-dead mutation, T cell activation assays, tumor rejection model, in vivo anergy induction\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in E3-dead mutation phenocopies full KO in multiple in vivo assays, directly demonstrates catalytic function requirement\",\n      \"pmids\": [\"21248250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Cbl-b controls the association between TLR4 and the intracellular adaptor MyD88 in monocytes after LPS stimulation. Expression of wild-type Cbl-b, but not E3 ligase-inactive Cbl-b, prevents NF-κB reporter activation in LPS-challenged monocytes. Cbl-b deficiency impairs TLR4 downregulation on neutrophil surfaces.\",\n      \"method\": \"Co-immunoprecipitation, reporter gene assay with E3 mutant, flow cytometry for surface TLR4, Cbl-b-/- mice, bone marrow chimeras\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of TLR4-MyD88 complex, E3 mutant rescue experiment, multiple cell types analyzed, single lab\",\n      \"pmids\": [\"17618294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Cbl-b interacts with P. aeruginosa ExoT and the ExoT substrate Crk in host cells. Following injection of ExoT into host cytosol, Cbl-b mediates ExoT polyubiquitination and proteasomal degradation. Cbl-b-/- mice (but not c-Cbl-/- mice) show increased bacterial dissemination specifically mediated by ExoT, establishing Cbl-b as essential for limiting ExoT-producing P. aeruginosa in vivo.\",\n      \"method\": \"Co-immunoprecipitation, in vitro and in vivo ubiquitination assay, mouse infection model, genetic KO comparison\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro plus in vivo evidence, genetic specificity (c-Cbl negative result), multiple orthogonal methods\",\n      \"pmids\": [\"17235393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cbl-b negatively regulates TCR-induced NF-κB activation via both PI3K/Akt-dependent and PKC-θ-dependent pathways. Cbl-b associates with PKC-θ upon TCR stimulation and regulates PKC-θ activation via Vav-1. PKC-θ then couples IKKs to the CARMA1-Bcl10-MALT1 complex. Hyperactivation of Akt in Cbl-b-/- cells may potentiate CARMA1-Bcl10-MALT1 complex formation.\",\n      \"method\": \"Co-immunoprecipitation, Cbl-b-/- T cells, NF-κB reporter assay, signaling pathway analysis, PKC-θ-/- crosses\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, genetic KO, reporter assay, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"18227156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Cbl-b deficiency increases macrophage recruitment in peritonitis via LFA-1 activation. Cbl-b deficiency increases phosphorylation of T758 in the LFA-1 β2-chain, enhancing association of 14-3-3β protein with the β2-chain and activating LFA-1. Disruption of the 14-3-3/β2-integrin interaction abrogated the enhanced ICAM-1 adhesion of Cbl-b-/- macrophages.\",\n      \"method\": \"Bone marrow chimera, LFA-1/β2-integrin phosphorylation analysis, co-immunoprecipitation (14-3-3/β2 interaction), LFA-1-/- and Cbl-b-/-LFA-1-/- double-KO epistasis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — double-KO epistasis plus biochemical Co-IP plus functional adhesion assay, single lab with orthogonal methods\",\n      \"pmids\": [\"18239087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PKC-θ associates with Cbl-b upon TCR stimulation and, after CD28 co-stimulation, mediates Cbl-b ubiquitination and proteasomal degradation in a PKC-θ kinase activity-dependent manner. PKC-θ-deficient T cell impaired responses are partially restored by concomitant loss of cblb, establishing a nonredundant antagonism between PKC-θ and Cbl-b.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, kinase-dead mutant, PKCθ-/- x cblb-/- double-KO genetic epistasis, T cell activation assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ubiquitination assay plus kinase-dead mutant plus genetic epistasis, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"19549985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Cbl-b binds to and promotes monoubiquitination of CARMA1. Ubiquitin conjugation to CARMA1 by Cbl-b disrupts CARMA1 complex formation with Bcl10 without affecting CARMA1 protein stability. CARMA1-/- NKT cells are defective in IFN-γ production. Cbl-b E3 ligase activity (RING finger) is critical for NKT anergy induction.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, RING finger mutant analysis, CARMA1-/- NKT cells, IFN-γ assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ubiquitination assay with RING finger mutant plus Co-IP plus genetic KO, single lab with multiple methods\",\n      \"pmids\": [\"19815501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Loss of Cbl-b in osteoclasts increases bone-resorbing activity, with increased RANKL-induced NF-κB, ERK, and p38 activation. Re-expression of Cbl-b in Cbl-b-/- osteoclast-like cells normalizes bone-resorbing activity; overexpression in WT cells inhibits bone resorption. Both functional TKB and RING finger domains are required for rescue.\",\n      \"method\": \"Genetic KO, osteoclast re-expression rescue, RING finger and TKB domain mutagenesis, bone resorption assay, RANKL signaling analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain mutagenesis rescue experiment plus KO plus functional bone resorption assay, single lab, orthogonal methods\",\n      \"pmids\": [\"19257814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cbl-b is a positive modulator of GPVI-dependent platelet signaling. Cbl-b constitutively associates with PLC-γ2 and BTK in platelets. Cbl-b-/- platelets display inhibited GPVI agonist-induced aggregation, secretion, Ca2+ mobilization, and reduced PLC-γ2 and BTK activation, while Syk activation is unaffected. Cbl-b thus acts downstream of Syk but upstream of BTK and PLC-γ2.\",\n      \"method\": \"Co-immunoprecipitation, Cbl-b-/- platelets, platelet aggregation assay, Ca2+ mobilization, in vivo thrombosis model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with multiple functional platelet assays plus Co-IP, in vivo thrombosis model, single lab\",\n      \"pmids\": [\"20400514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Autoinhibition of Cbl-b E3 activity is achieved through intramolecular interaction whereby the unphosphorylated N-terminal region masks the RING domain interaction surface with E2 ubiquitin-conjugating enzyme. Phosphorylation of Y363 (in the helix-linker region between TKB and RING domains) disrupts this interdomain interaction to expose the E2 binding surface and also enhances binding to E2 (UbcH5B) by reducing electrostatic repulsion through proximity of the phosphate group to the interaction surface.\",\n      \"method\": \"NMR, small-angle X-ray scattering (SAXS), phosphorylation-mimicking mutants, E2 binding assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure plus SAXS plus E2 binding assay with phosphomimetic mutants, single lab with multiple orthogonal structural and biochemical methods\",\n      \"pmids\": [\"22158902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cbl-b directly interacts with and ubiquitinates SMAD7, a negative regulator of TGFβ receptor signaling, targeting it for degradation. SMAD7 protein levels (but not mRNA) are elevated in cblb-/- T cells. Genetic loss of SMAD7 in cblb-/- mice restores TGFβ sensitivity in T cell cytokine responses and abrogates the tumor rejection phenotype.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, SMAD7 protein/mRNA analysis, double-KO genetic epistasis (cblb-/- x SMAD7-/-), tumor rejection model\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ubiquitination assay plus Co-IP plus genetic epistasis in vivo, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23709694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cbl-b ubiquitinates and degrades IGF-IR in gastric cancer cells, thereby inhibiting the Akt/ERK-miR-200c-ZEB2 axis and suppressing IGF-I-induced epithelial-mesenchymal transition.\",\n      \"method\": \"shRNA knockdown, ubiquitination assay, co-immunoprecipitation, signaling pathway analysis, patient tissue correlation\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay plus Co-IP plus shRNA rescue, single lab\",\n      \"pmids\": [\"24885194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The TAM receptor tyrosine kinases Tyro3, Axl, and Mer (Mertk) are direct ubiquitylation substrates for Cbl-b in NK cells. Cbl-b mediates NK cell inhibition downstream of TAM receptors. Genetic deletion or targeted inactivation of Cbl-b E3 ligase activity licenses NK cells to reject metastatic tumors. A TAM kinase inhibitor and warfarin exert anti-metastatic activity through the Cbl-b/TAM pathway.\",\n      \"method\": \"Ubiquitination assay, knockout mice (E3 ligase-dead knock-in), NK cell functional assays, tumor metastasis models, TAM kinase inhibitor\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ubiquitination assays with TAM substrates, E3 ligase-dead knock-in, multiple in vivo tumor models, mechanistic pathway established\",\n      \"pmids\": [\"24553136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cbl-b associates with Stat6 upon IL-4 ligation and targets Stat6 for ubiquitination and degradation. This process is heightened in the presence of TCR/CD28 co-stimulation. K108 and K398 of Stat6 were identified as ubiquitination sites. Loss of Cbl-b facilitates Th2 and Th9 cell differentiation; Stat6 deficiency in Cblb-/- mice abrogates hyper-Th2 responses.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, site mutagenesis (K108, K398), double-KO genetic epistasis (Cblb-/- x Stat6-/-), T cell differentiation assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ubiquitination assay with site mutagenesis plus Co-IP plus genetic epistasis, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"24508458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Myostatin induces Cblb expression in a Smad3-dependent manner. Elevated Cblb results in ubiquitin-proteasome-mediated degradation of IRS1, contributing to insulin resistance. Overexpression or knockdown of Cblb has major impact on IRS1 and pAkt levels in the presence or absence of insulin.\",\n      \"method\": \"Overexpression/knockdown of Cblb, IRS1 ubiquitination assay, Western blot, Smad3-dependent reporter\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay plus knockdown/overexpression plus Smad3 pathway analysis, single lab\",\n      \"pmids\": [\"24451368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SHP-1 is recruited to Cbl-b and dephosphorylates it upon CD3 stimulation, preventing Cbl-b tyrosine phosphorylation and subsequent ubiquitination/degradation. CD28 co-stimulation abrogates SHP-1-Cbl-b interaction. T cells lacking SHP-1 display heightened tyrosine phosphorylation and ubiquitination of Cbl-b, with decreased Cbl-b protein levels.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assay, SHP-1-/- conditional knockout T cells, overexpression rescue, in vitro Th2 differentiation, in vivo allergy model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus phosphorylation assay plus conditional KO plus overexpression rescue in vitro and in vivo, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"26416283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Cbl-b and c-Cbl target the osteogenic transcription factor Osterix for ubiquitin-proteasome-mediated degradation, inhibiting BMP2-induced osteoblast differentiation in mesenchymal cells.\",\n      \"method\": \"Overexpression, co-immunoprecipitation, ubiquitination assay, osteoblast differentiation assay\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay plus Co-IP plus functional differentiation assay, single lab\",\n      \"pmids\": [\"25744063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CBLB associates with SYK and ubiquitinates SYK, dectin-1, and dectin-2 after fungal recognition in macrophages and dendritic cells, controlling proximal CLR signaling. CBLB deficiency results in increased inflammasome activation, enhanced reactive oxygen species production, and increased fungal killing. A cell-permeable CBLB inhibitory peptide protects mice from lethal C. albicans infections.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, Cblb-/- mice, inflammasome/ROS assays, in vivo infection model\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ubiquitination assay plus Co-IP plus genetic KO plus in vivo model, replicated in parallel paper (PMID:27428899)\",\n      \"pmids\": [\"27428901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CBLB directs polyubiquitination of dectin-1 and dectin-2 and their downstream kinase SYK, inhibiting dectin-1- and dectin-2-mediated innate immune responses against Candida albicans. CBLB mediates ubiquitination of activated CLRs through association via adapter protein FcR-γ and tyrosine kinase SYK. Ubiquitinated CLRs are sorted to lysosomes for degradation by the ESCRT system.\",\n      \"method\": \"Ubiquitination assay, co-immunoprecipitation, Cblb-/- mice, dectin-1/2-/- double-KO epistasis, ESCRT subunit knockdown, in vivo infection model\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ubiquitination assay plus Co-IP plus genetic epistasis with multiple KOs plus in vivo model, replicated in parallel paper (PMID:27428901)\",\n      \"pmids\": [\"27428899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Cbl-b negatively regulates CLR (Dectin-2 and Dectin-3)-mediated antifungal signaling by mediating ubiquitination of these activated CLRs through association via FcR-γ and Syk. Ubiquitinated CLRs are sorted to lysosomes via the ESCRT system. Deficiency of Cbl-b or ESCRT subunits significantly decreases CLR degradation and increases proinflammatory cytokine production.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, Cblb-/- mice, ESCRT knockdown, cytokine measurement, in vivo infection\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ubiquitination assay plus Co-IP plus Cblb-/- mice plus ESCRT knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"27432944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CD5 transmembrane receptor constitutes a key scaffold for CBL- and CBLB-mediated ubiquitylation following TCR engagement. CBLB signaling complexes were characterized over 600 seconds of TCR stimulation, identifying both known and novel CBLB-interacting partners.\",\n      \"method\": \"Affinity purification coupled to quantitative mass spectrometry, mouse genetics, biochemical analysis\",\n      \"journal\": \"Molecular systems biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative AP-MS with biochemical follow-up, single lab, novel scaffold function for CD5\",\n      \"pmids\": [\"27474268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CBLB forms a complex with CD81, CAPN5, and other proteins in human liver cells. CBLB and CAPN5 support HCV entry at a post-binding, pre-replication step. Knockout of CBLB reduced susceptibility to all tested HCV genotypes but not to vesicular stomatitis virus or human coronavirus.\",\n      \"method\": \"Quantitative proteomics (CD81 interactome), CBLB/CAPN5 knockout, HCV infection assay\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative proteomics plus genetic knockout plus functional viral entry assay, single lab\",\n      \"pmids\": [\"30024968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TAM receptors (Tyro3, Axl, Mer) attenuate NK cell responses via E3 ubiquitin ligase Cbl-b. Specifically, Tyro3, Axl, and Mer phosphorylate Cbl-b at tyrosine residues 133 and 363 (Tyro3 shown specifically). Gas6 ligation induces degradation of LAT1 (transmembrane adaptor for NK activating receptor signaling) in WT but not Cbl-b knockout NK cells, in a TAM kinase- and Cbl-b-dependent manner.\",\n      \"method\": \"Phosphorylation assay (Tyr133, Tyr363 on Cbl-b), Cbl-b-/- NK cells, Gas6 ligation, LAT1 degradation assay, NK cell functional assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation site identification plus KO cell functional assays plus LAT1 degradation, single lab\",\n      \"pmids\": [\"31531847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cbl-b ubiquitinates GluN2B subunits of NMDA receptors in spinal cord dorsal horn neurons through its N-terminal TKB domain. This ubiquitination decreases GluN2B-containing NMDAR-mediated synaptic transmission. Cbl-b abundance increases from P1 to P14, limiting synaptic GluN2B during development. Peripheral inflammation causes dephosphorylation of Cbl-b at Tyr363, impairing its binding to and ubiquitylation of GluN2B, enabling reappearance of GluN2B-containing NMDARs. A phosphomimetic Cbl-b mutant suppresses GluN2B-mediated synaptic currents and inflammatory pain.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, synaptic fractionation, electrophysiology, in vivo knockdown, phosphomimetic mutant, inflammatory pain model\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ubiquitination assay plus electrophysiology plus phosphomimetic mutant plus in vivo knockdown, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32606037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cbl-b mediates K27-linked ubiquitination of lysine 164 of STAT5a in dendritic cells, targeting STAT5 for degradation to promote cell apoptosis. c-Cbl mediates K29-linked ubiquitination of lysine 696 of STAT5a and K27-linked ubiquitination of lysine 140 and 694 of STAT5b. Loss of Cbl-b and c-Cbl in DCs results in sustained STAT5 activity, reduced Bim expression, and impaired cDC1 apoptosis.\",\n      \"method\": \"Conditional double-knockout mice (DC-specific), co-immunoprecipitation, ubiquitination assay with linkage and site specificity, apoptosis assay\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay with site specificity, Co-IP, conditional KO, single lab\",\n      \"pmids\": [\"35354799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TCR stimulation induces formation of a molecular complex between Cbl-b and STS1 (a pH-sensitive unconventional phosphatase). The interaction depends on a proline motif in Cbl-b interacting with the STS1 SH3 domain. STS1 dephosphorylates Cbl-b-interacting phosphoproteins. Deficiency of STS1 or Cbl-b diminishes T cell sensitivity to acidic environments, promotes T cell activity in vivo, and inhibits tumor growth.\",\n      \"method\": \"Co-immunoprecipitation, phosphatase assay, proline motif mutagenesis, STS1-/- and Cbl-b-/- cells, tumor model\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mutagenesis plus phosphatase assay plus genetic KO models plus in vivo tumor model, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"38091950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Co-crystal structure of Cbl-b with the small-molecule inhibitor C7683 (an analogue of clinical candidate Nx-1607) reveals that the compound interacts with both the TKBD and LHR domains of Cbl-b, but not the RING domain, locking Cbl-b in an inactive autoinhibited conformation by acting as an intramolecular glue.\",\n      \"method\": \"X-ray crystallography (co-crystal structure), biophysical binding assays, cellular activity assays\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — co-crystal structure plus biophysical validation, defines inhibitor mechanism at atomic resolution\",\n      \"pmids\": [\"38104184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cbl-b independently regulates EGFR through preferential direct binding to phosphorylated Y1045 of EGFR (unlike c-Cbl which relies mainly on Grb2-dependent indirect interaction). Overexpression of E3-dead Cbl-b slows EGF-induced degradation of active EGFR and diminishes EGF-guided chemotaxis, demonstrating distinct modes of EGFR regulation by Cbl and Cbl-b.\",\n      \"method\": \"Inducible expression of E3-dead mutants, EGFR binding/ubiquitination assay, endocytosis assay, cell migration assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — E3-dead mutant analysis plus functional EGFR binding/trafficking/migration assays, single lab\",\n      \"pmids\": [\"37903221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CBL and CBLB ubiquitinate ICOS in CD4+ T cells, restraining BCL6 expression by promoting ICOS degradation. Loss of CBLs allows ICOS signaling to attenuate BCL6 degradation via chaperone-mediated autophagy (CMA), promoting hyper Tfh cell responses. T cell-specific CBLs-deficient mice develop hyper Tfh responses and SLE; blockade of Tfh development prevents SLE.\",\n      \"method\": \"Conditional T cell-specific double-KO mice, ubiquitination assay (ICOS), genetic epistasis (Tfh blockade), CMA analysis, BCL6 protein stability assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay plus conditional KO plus genetic epistasis plus in vivo SLE model, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"38761804\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CBLB encodes a RING-type E3 ubiquitin ligase that functions as a master negative regulator of immune cell activation by ubiquitinating a broad range of substrates—including PI3K p85, Vav1, Syk, CARMA1, Stat6, SMAD7, ICOS, TAM receptors (Tyro3/Axl/Mer), dectin-1/2, TLR4-MyD88 complex components, and receptor tyrosine kinases (EGFR, IGF-IR, KIT, FLT3)—to set activation thresholds in T cells, B cells, NK cells, mast cells, and innate immune cells; its E3 activity is autoinhibited by intramolecular TKBD-RING interaction and activated by Tyr363 phosphorylation (mediated by Src/Syk family kinases or TAM receptors), and is counteracted by SHP-1-mediated dephosphorylation or degraded following CD28/PKC-θ co-stimulation, thereby coupling co-stimulatory signal strength to the amplitude and duration of downstream immune responses.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CBLB encodes a RING-type E3 ubiquitin ligase that functions as a master negative regulator of immune cell activation, setting the threshold and duration of antigen- and cytokine-receptor signaling across T cells, B cells, NK cells, mast cells, and innate myeloid cells [#6, #22, #34]. Its catalytic role is direct and central: selective genetic inactivation of CBLB E3 activity phenocopies total ablation, producing T-cell hyperactivation, spontaneous autoimmunity, impaired anergy, and spontaneous tumor rejection [#22]. CBLB couples co-stimulatory signal strength to response amplitude through two layered controls. First, in resting T cells it restrains TCR signaling by ubiquitinating and limiting the PI3K p85 subunit—an action that is proteolysis-independent and controls p85 recruitment to CD28/TCR-zeta—and by suppressing Vav1 activation, such that its loss uncouples proliferation and IL-2 production from CD28 co-stimulation [#7, #8, #10]. Second, CBLB itself is regulated by phosphorylation: autoinhibition by an intramolecular interaction masks the RING/E2 surface, and phosphorylation of Tyr363 disrupts this interaction to license E2 (UbcH5B) engagement [#31], while SHP-1 dephosphorylates CBLB to protect it from degradation and CD28/PKC-theta co-stimulation drives its ubiquitination and proteasomal destruction [#27, #37]. Through its ligase activity CBLB targets a broad substrate repertoire to terminate or tune signaling: Syk and CARMA1 in lymphocyte antigen receptor pathways [#17, #28], Stat6 to restrain Th2/Th9 differentiation [#35], SMAD7 to set TGF-beta sensitivity and tumor immunity [#32], ICOS to restrain Tfh responses and prevent lupus-like autoimmunity [#50], TAM receptors (Tyro3/Axl/Mer) and their adaptor LAT1 in NK cells [#34, #44], the TLR4–MyD88 complex in monocytes [#23], and Syk/dectin-1/dectin-2 in antifungal C-type lectin receptor signaling, routing activated receptors to lysosomal degradation via the ESCRT machinery [#39, #40, #41]. Beyond immunity, CBLB ubiquitinates and degrades receptor tyrosine kinases including EGFR, KIT, and IGF-IR to limit their signaling and trafficking [#11, #19, #33], and a nonsense mutation in Cblb is the causative susceptibility allele for type 1 diabetes in the KDP rat, with wild-type transgene rescuing the phenotype [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing CBLB as an adaptor-type signaling regulator answered whether it physically couples to the cytoplasmic signaling apparatus, revealing a RING-finger protein with a proline-rich domain that engages SH3-containing partners.\",\n      \"evidence\": \"Molecular cloning and SH3-domain binding assays defining the proline-rich/RING-finger architecture\",\n      \"pmids\": [\"7784085\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No catalytic activity demonstrated\", \"No physiological substrate identified\", \"Functional consequence of binding unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Linking CBLB to Vav and growth-factor receptors addressed how it intersects RTK signaling, showing it forms trimeric complexes with activated receptors and dampens Vav-driven JNK activation.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, and JNK activation assays in fibroblasts\",\n      \"pmids\": [\"9399639\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of JNK inhibition unresolved\", \"Overexpression-based, not endogenous\", \"No ubiquitination tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identifying the TCR-proximal kinases that phosphorylate CBLB answered how antigen-receptor engagement activates it, mapping Syk/ZAP-70 and Src-family kinase inputs and Crk-L docking sites.\",\n      \"evidence\": \"Co-IP, in vitro kinase assays, and mutagenesis in Jurkat T cells\",\n      \"pmids\": [\"10022120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional outcome of each phosphosite not resolved\", \"Catalytic activity not yet demonstrated\", \"Endogenous substrate unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Knockout mice answered the central physiological question of CBLB function, establishing it as a negative regulator that sets the CD28 co-stimulation threshold by selectively suppressing TCR-driven Vav1 activation.\",\n      \"evidence\": \"Gene-targeted Cbl-b knockout mice with proliferation, IL-2, signaling readouts, and CD28-/- genetic complementation\",\n      \"pmids\": [\"10646608\", \"10646609\", \"11070165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of Vav suppression not yet defined\", \"Whether ubiquitination is required not yet tested\", \"Substrate at the receptor unidentified at this stage\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that CBLB is a RING-type E3 ligase targeting PI3K p85 answered how it executes negative regulation biochemically, and a later study showed this control is proteolysis-independent and governs p85 recruitment to CD28/TCR.\",\n      \"evidence\": \"In vitro ubiquitination assays, domain-deletion mutagenesis, Co-IP, and PI3K-inhibitor rescue in Cbl-b-/- T cells\",\n      \"pmids\": [\"11087752\", \"11526404\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Non-degradative mechanism of p85 regulation incompletely defined\", \"Ubiquitin chain linkage on p85 not characterized\", \"Relationship to Vav suppression unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defining CBLB-mediated EGFR ubiquitination and reciprocal self-degradation answered how it terminates RTK signaling, showing it shortens receptor activation and is itself degraded as part of a feedback loop.\",\n      \"evidence\": \"Ubiquitination assays, domain mutagenesis, and proteasomal/lysosomal inhibitor experiments in EGFR-expressing cells\",\n      \"pmids\": [\"10086340\", \"10542134\", \"11375397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell ubiquitin linkage types not defined\", \"Quantitative contribution of degradative vs non-degradative routes unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying a causative Cblb nonsense mutation in the KDP rat answered whether CBLB controls autoimmunity in vivo, establishing it as a genetically validated type 1 diabetes susceptibility gene through transgenic rescue.\",\n      \"evidence\": \"Positional cloning and transgenic complementation in a spontaneous diabetes rat model\",\n      \"pmids\": [\"12118252\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular target population of the diabetes phenotype not pinpointed\", \"Substrate relevant to autoimmunity not identified here\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Extending CBLB function to B cells and TCR trafficking answered how broadly its negative regulation operates, showing roles in PLC-gamma2 signaling and Cbl-family-dependent clearance of engaged TCR from the cell surface.\",\n      \"evidence\": \"DT40 and c-Cbl/Cbl-b double-knockout systems, Co-IP, Ca2+ mobilization, and TCR internalization/lysosome trafficking assays\",\n      \"pmids\": [\"12093870\", \"12415267\", \"12177062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Distinct positive vs negative roles in B cells mechanistically separate\", \"CIN85-dependent internalization vs ubiquitination contributions context-dependent\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identifying Syk as a BCR-proximal ubiquitination substrate answered how CBLB terminates antigen-receptor signaling in B cells, linking sustained Syk phosphorylation to loss of Syk ubiquitination.\",\n      \"evidence\": \"Cbl-b knockout B cells, BCR stimulation, ubiquitination assays, and imaging\",\n      \"pmids\": [\"12771181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Syk ubiquitin chain linkage and fate not fully defined\", \"Stoichiometry of Syk regulation unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Extending CBLB to mast cell FceRI signaling, KIT degradation, and defining its polyubiquitin-binding UBA domain answered how it operates across innate effector cells and distinguished it functionally from c-Cbl.\",\n      \"evidence\": \"Lipid-raft fractionation, RING-finger mutagenesis, ubiquitination/degradation assays, and GST pull-downs comparing UBAb vs UBAc\",\n      \"pmids\": [\"14604964\", \"15315962\", \"15273720\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Role of UBA polyubiquitin binding in substrate selection not fully resolved\", \"In vivo relevance of Gab2/KIT targeting incompletely defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"An E3-ligase-dead knock-in answered the decisive question of whether catalytic activity underlies CBLB function in vivo, showing the catalytic mutation phenocopies full ablation in autoimmunity, anergy, and tumor rejection.\",\n      \"evidence\": \"Knock-in mice carrying an E3 ligase-dead mutation with in vivo T-cell, anergy, and tumor-rejection assays\",\n      \"pmids\": [\"21248250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytically relevant in vivo substrates not enumerated here\", \"Cell-type-specific contributions not dissected\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defining CBLB control of the TLR4–MyD88 complex and ExoT degradation answered how it regulates innate antibacterial responses, requiring E3 activity for NF-kB suppression and host defense in vivo.\",\n      \"evidence\": \"Co-IP, E3-mutant reporter assays, and Cbl-b-/- mouse infection models\",\n      \"pmids\": [\"17618294\", \"17235393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ubiquitination of TLR4/MyD88 components vs complex disruption not fully separated\", \"Tissue-specific innate contributions incompletely mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connecting CBLB to NF-kB regulation, PKC-theta/CARMA1 signaling, and integrin (LFA-1) activation broadened the picture of how it tunes downstream activation modules in lymphocytes and myeloid cells.\",\n      \"evidence\": \"Co-IP, Cbl-b-/- T cells, NF-kB reporters, and LFA-1/14-3-3 biochemistry with double-knockout epistasis\",\n      \"pmids\": [\"18227156\", \"18239087\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PKC-theta/NF-kB regulation is ubiquitination-dependent not resolved here\", \"Direct substrate in the integrin pathway not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying CARMA1 as a non-degradative monoubiquitination substrate and mapping PKC-theta-driven CBLB degradation answered how co-stimulation reciprocally controls CBLB and how it disrupts signaling complexes without proteolysis.\",\n      \"evidence\": \"Ubiquitination assays with RING mutants, Co-IP, kinase-dead mutants, and PKC-theta/Cbl-b double-knockout epistasis\",\n      \"pmids\": [\"19815501\", \"19549985\", \"19257814\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of non-degradative monoubiquitination across substrates unclear\", \"Determinants of degradative vs non-degradative outcomes not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrating a positive role in platelet GPVI signaling answered whether CBLB is uniformly inhibitory, showing it acts as a positive modulator downstream of Syk but upstream of BTK/PLC-gamma2 in some contexts.\",\n      \"evidence\": \"Cbl-b-/- platelets, aggregation/Ca2+ assays, Co-IP, and an in vivo thrombosis model\",\n      \"pmids\": [\"20400514\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the positive (vs negative) role unresolved\", \"Whether ligase activity is required not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The structural basis of autoinhibition answered how CBLB activity is gated, showing the unphosphorylated N-terminus masks the RING–E2 surface and Tyr363 phosphorylation relieves this and enhances E2 (UbcH5B) binding.\",\n      \"evidence\": \"NMR, SAXS, phosphomimetic mutants, and E2-binding assays\",\n      \"pmids\": [\"22158902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of activation in the full-length receptor-bound state not resolved\", \"Quantitative kinetics of de-autoinhibition not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying SMAD7, Stat6, IGF-IR, and the TAM receptors as substrates answered how CBLB controls TGF-beta sensitivity, Th2/Th9 differentiation, RTK-driven EMT, and NK-cell anti-metastatic activity, including therapeutic targeting of the CBLB/TAM axis.\",\n      \"evidence\": \"Ubiquitination assays with site mutagenesis, Co-IP, genetic epistasis (Cblb x Smad7, Cblb x Stat6), shRNA, E3-dead knock-in NK cells, and tumor-metastasis models\",\n      \"pmids\": [\"23709694\", \"24508458\", \"24885194\", \"24553136\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hierarchy among substrates in a given cell context not defined\", \"In vivo contribution of IGF-IR targeting limited to cancer models\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining SHP-1-mediated dephosphorylation of CBLB answered how its phosphorylation-dependent activity and stability are reversed, with CD28 co-stimulation abrogating the SHP-1 interaction.\",\n      \"evidence\": \"Co-IP, phosphorylation assays, SHP-1 conditional knockout T cells, and in vitro/in vivo allergy models\",\n      \"pmids\": [\"26416283\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect SHP-1 action on specific phosphosites not fully mapped\", \"Other phosphatases not excluded\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Establishing CBLB control of C-type lectin receptor antifungal signaling answered how it tunes innate fungal recognition, showing ubiquitination of Syk/dectin-1/dectin-2 via FcR-gamma and ESCRT-dependent lysosomal sorting, with a CBLB inhibitory peptide protecting against Candida.\",\n      \"evidence\": \"Ubiquitination assays, Co-IP, Cblb-/- mice, dectin double-knockout epistasis, ESCRT knockdown, and in vivo infection models\",\n      \"pmids\": [\"27428901\", \"27428899\", \"27432944\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate prioritization (receptor vs Syk) not resolved\", \"Linkage specificity of CLR ubiquitination not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Systems-level mapping of the CBLB TCR-signaling interactome answered which scaffolds assemble CBLB complexes over time, identifying CD5 as a key scaffold for Cbl/CBLB-mediated ubiquitylation.\",\n      \"evidence\": \"Affinity-purification quantitative mass spectrometry with mouse genetics over a TCR-stimulation time course\",\n      \"pmids\": [\"27474268\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of CD5 scaffolding on specific substrates not defined\", \"Novel partners not individually validated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"A non-ubiquitin role in viral entry answered whether CBLB has functions beyond signaling termination, showing it acts with CD81/CAPN5 to support HCV entry at a post-binding step.\",\n      \"evidence\": \"CD81 interactome proteomics, CBLB/CAPN5 knockout, and HCV infection assays across genotypes\",\n      \"pmids\": [\"30024968\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether E3 activity is required not tested\", \"Mechanism of entry support undefined\", \"Direct vs indirect role unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extending CBLB to neurons answered whether its ubiquitin activity operates outside the immune system, showing it ubiquitinates NMDAR GluN2B in spinal cord and that inflammation-driven Tyr363 dephosphorylation drives inflammatory pain.\",\n      \"evidence\": \"Ubiquitination assays, synaptic fractionation, electrophysiology, phosphomimetic mutants, and an inflammatory pain model\",\n      \"pmids\": [\"32606037\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TKB-domain-based substrate recognition mechanism for GluN2B not fully defined\", \"Generality to other CNS receptors unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining linkage- and site-specific STAT5 ubiquitination answered how CBLB and c-Cbl distinctly control dendritic cell survival, with CBLB mediating K27-linked ubiquitination of STAT5a K164 to promote apoptosis.\",\n      \"evidence\": \"DC-specific conditional double-knockout mice, Co-IP, and linkage/site-specific ubiquitination and apoptosis assays\",\n      \"pmids\": [\"35354799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional separation of CBLB vs c-Cbl STAT5 targeting in vivo not fully resolved\", \"Linkage determinants not mechanistically explained\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identifying the STS1 phosphatase complex, the EGFR-Y1045 direct binding mode, and the structural basis of small-molecule inhibition answered how CBLB activity is fine-tuned, paralog-distinguished, and therapeutically lockable in an autoinhibited state.\",\n      \"evidence\": \"Co-IP with domain mutagenesis, phosphatase assays, E3-dead EGFR trafficking assays, and a co-crystal structure with an Nx-1607 analogue\",\n      \"pmids\": [\"38091950\", \"37903221\", \"38104184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of STS1-mediated pH sensing across tissues not defined\", \"Generality of the Y1045 binding mode to other substrates unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying ICOS as a CBL/CBLB substrate answered how it restrains follicular helper T cell programs, showing ICOS ubiquitination limits BCL6 stability and prevents lupus-like autoimmunity.\",\n      \"evidence\": \"T-cell-specific conditional double-knockout mice, ICOS ubiquitination assays, BCL6 stability analysis, and an in vivo SLE model with Tfh blockade\",\n      \"pmids\": [\"38761804\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative CBLB vs c-Cbl contribution to ICOS targeting not separated\", \"Connection to chaperone-mediated autophagy of BCL6 mechanistically incomplete\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CBLB selects among its diverse substrates, chooses ubiquitin chain linkages, and switches between degradative, trafficking-directed, and complex-disrupting (non-degradative) outcomes in a cell-type- and context-specific manner remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of substrate prioritization across immune and non-immune cells\", \"Determinants of degradative vs non-degradative ubiquitination undefined\", \"Quantitative rules linking co-stimulation strength to substrate fate unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [8, 11, 19, 22, 34]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [8, 17, 28, 32, 35, 39]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 7, 10, 23]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 2, 5, 14]},\n      {\"term_id\": \"GO:0031386\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10, 24]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [18, 9]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 17, 23, 34, 39, 50]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 10, 25, 32]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [8, 11, 19, 32, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 33, 50]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [46]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"VAV1\", \"SYK\", \"PI3K p85\", \"GRB2\", \"EGFR\", \"CIN85\", \"PKC-theta\", \"STS1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}